

L24 + Ascorbil palmitate

L25 3 ANSWERS USPATFULL
AN 1999:110380 USPATFULL
TI Use of flavones and flavonoids against the UV-induced decomposition of
dibenzoylmethane and its derivatives
NCL NCLM: 514/685.000
NCLS: 203/078.000; 424/047.000; 424/059.000

IC [6]
ICM: A61K031-12
GI

SECTION	PAGES	FORMAT	SIZE
FRONT PAGE	1	PAGE.FP	28K
DESCRIPTION	2-9	PAGE.DESC	602K
CLAIMS	9-9	PAGE.CLM	60K
COMPLETE	1-9	PAGE.ALL	630K

Use PAGE(n) to retrieve a specific page

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L25 3 ANSWERS USPATFULL
AN 2001:71074 USPATFULL
TI Self-tanning dihydroxyacetone formulations having improved stability and
providing enhanced delivery
NCL NCLM: 424/059.000
NCLS: 424/060.000; 424/400.000; 424/401.000

IC [7]
ICM: A61K007-42
ICS: A61K007-44; A61K007-00
GI

SECTION	PAGES	FORMAT	SIZE
FRONT PAGE	1	PAGE.FP	64K
DESCRIPTION	2-18	PAGE.DESC	1795K
CLAIMS	18-20	PAGE.CLM	186K
COMPLETE	1-20	PAGE.ALL	2003K

Use PAGE(n) to retrieve a specific page

L25 3 ANSWERS USPATFULL
AN 1998:108008 USPATFULL
TI Pharmaceutical compositions and methods for protecting and treating sun
damaged skin
NCL NCLM: 424/059.000
NCLS: 424/060.000; 424/400.000; 424/401.000

IC [6]
ICM: A61K007-42
ICS: A61K007-44; A61K007-00
GI

SECTION	PAGES	FORMAT	SIZE
FRONT PAGE	1	PAGE.FP	92K
DESCRIPTION	2-10	PAGE.DESC	977K
CLAIMS	10-10	PAGE.CLM	114K
COMPLETE	1-10	PAGE.ALL	1070K

Use PAGE(n) to retrieve a specific page

ALL ANSWERS HAVE BEEN SCANNED

=>

181) *Europe*

L5 ANSWER 1 OF 18 USPATFULL

ACCESSION NUMBER: 2001:229235 USPATFULL
TITLE: METHOD FOR USING SOLUBLE CURCUMIN TO INHIBIT
PHOSPHORYLASE KINASE IN INFLAMMATORY DISEASES
INVENTOR(S): HENG, MADALENE C.Y., NORTHRIDGE, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001051184	A1	20011213
APPLICATION INFO.:	US 1999-315856	A1	19990520 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ATTN: DAVID A. FARAH. M.D., SHELDON & MAK, 225 SOUTH LAKE AVENUE, SUITE 900, PASADENA, CA, 91101		
NUMBER OF CLAIMS:	115		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	4191		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compound curcumin, derived from turmeric, inhibits phosphorylase kinase and, by doing so, exhibits a number of physiological effects related to the control of inflammation and cellular proliferation. However, curcumin is effective only when in solution. Curcumin is almost completely insoluble in water or in oils, but is soluble in alcohols. Accordingly, a method for treating inflammation in a mammal comprising administering curcumin in a solution containing at least one alcohol to a mammal to detectably inhibit the activity of phosphorylase kinase in the blood of the mammal or in a tissue of the mammal. The alcohol is preferably ethanol, 1-propanol, or 2-propanol; most preferably, it is ethanol. Instead of curcumin, a curcumin derivative or curcuminoid can be administered. The method can further comprise the administration of at least one additional compound that can be (1) vitamin D.sub.3 and vitamin D.sub.3 analogues; (2) vitamin A, vitamin A derivatives, and vitamin A analogues (3) a calmodulin inhibitor; (4) an anti-inflammatory drug; (5) a calcium channel blocker; (6) a H1 or H2 histamine blocker; (7) an antioxidant; (8) a polyphenolic compound; (9) a monoterpene; (10) genistein; (11) a soybean derived lectin; and (12) dehydrozingerone. Another aspect of the present invention is a pharmaceutical composition comprising curcumin, a curcuminoid, or a curcumin derivative in a solution containing at least one alcohol, at least one additional compound as described above, and a pharmaceutically acceptable carrier.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 18 USPATFULL

ACCESSION NUMBER: 2001:109984 USPATFULL
TITLE: TREATMENT OF PRURITUS WITH VITAMIN D AND ANALOGS
THEREOF
INVENTOR(S): STRUBE, MARILYN E., BELLEVILLE, IL, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001007866	A1	20010712
APPLICATION INFO.:	US 1998-123885	A1	19980728 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-720698, filed on 2 Oct 1996, GRANTED, Pat. No. US 5789399		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5030	19951010 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DONALD R HOLLAND, ARMSTRONG TEASDALE LLP, ONE
METROPOLITAN SQUARE, SUITE 2600, ST LOUIS, MO,
63102-2740

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 841

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating pruritus comprising topical administration of
formulation of vitamin D or an analog of vitamin D is disclosed. The
formulation comprises a therapeutically effective, water-based emulsion,
water-based suspension or oil-based formulation of vitamin D or analog
of vitamin D.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:441622 CAPLUS
DOCUMENT NUMBER: 133:63997
TITLE: Topical treatment of skin diseases with compositions
containing lysine or analogs thereof
INVENTOR(S): Wulf, Hans Christian
PATENT ASSIGNEE(S): Aps Kbus 8 Nr. 4788, Den.
SOURCE: PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037071	A1	20000629	WO 1999-DK722	19991221
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			DK 1998-1691	A 19981221
			US 1998-113751	P 19981223

AB The invention concerns the use of lysine and/or lysine analogs in a
topical treatment of skin diseases. The medicaments can be formulated
with addnl. active agents for topical or systemic administration. A
topical soln. contained tranexamic acid 10, methylparaben 0.08,
propylparaben 0.02, and purified water 89.9 g.

REFERENCE COUNT: 11
REFERENCE(S): (1) Agrimmune Inc; WO 9712582 A2 1997 CAPLUS
(2) Ayala, E; 1989, V28(1), P16 CAPLUS
(3) Bioscientific Limited; WO 9747276 A1 1997 CAPLUS
(4) Hao; 1997, V25(2), P121 CAPLUS
(5) Richard, M; US 5720948 A 1998 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 18 USPATFULL

ACCESSION NUMBER: 2000:171025 USPATFULL
TITLE: External ophthalmic preparation containing vitamin D
INVENTOR(S): Kita, Kiyoshi, 4-4-7-502 Honmachi, Shibuya-ku, Tokyo

151, Japan

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6162801		20001219
	WO 9718817		19970529
APPLICATION INFO.:	US 1998-11622		19980212 (9)
	WO 1996-JP1082		19960422
			19980212 PCT 371 date
			19980212 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-335587	19951120
	JP 1995-349929	19951213
	JP 1995-351708	19951218
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fay, Zohreh	
LEGAL REPRESENTATIVE:	Staas & Halsey LLP	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	931	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An ophthalmic composition, containing ergocalciferol or cholecalciferol, i.e., an inactive vitamin D, as the active ingredient, for treating and conditioning damaged tissue of the region of the eye. An ophthalmic composition for preventing and treating disturbed metabolism in eye tissues, such as "dry eye", including a vitamin D or an active vitamin D as the active ingredient. An ophthalmic composition or a dermatological composition for protecting the skin or eyes from harmful ultraviolet radiation including a vitamin D or a vitamin K as the active ingredient. The ophthalmic composition normalizes the transparency or refraction of the eyeballs when administered to the region of the eye, and contributes to the amendment, healing or prevention of symptoms due to disturbed metabolism in eye tissue. The dermatological composition protects the skin and scalp from harmful ultraviolet radiation. It is possible to supply vitamin D to the skin by applying the vitamin D-containing dermatological composition via a cosmetic.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 18 USPTFULL

ACCESSION NUMBER: 1999:27178 USPTFULL
TITLE: Ophthalmic composition containing active Vitamin D
INVENTOR(S): Itoh, Seiji, Mobara, Japan
Ishii, Yasuo, Kawaguchi, Japan
Mukai, Katsuhiko, Kashiwa, Japan
Kita, Kiyoshi, Tokyo, Japan
PATENT ASSIGNEE(S): New Vision Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5876709		19990302
APPLICATION INFO.:	US 1997-863425		19970527 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos A.		
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		

LINE COUNT: 1373

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An ophthalmic composition for preventing corneal haze and corneal refraction anomaly observed after anterior ocular tissues are damaged or during corneal diseases comprises, as an effective component, vitamin D such as ergocalciferols and cholecalciferols or active vitamin D.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 18 USPATFULL

ACCESSION NUMBER: 1998:92021 USPATFULL

TITLE: Treatment of pruritus with vitamin D and analogs thereof

INVENTOR(S): Strube, Marilyn E., 1017 Olive St., Belleville, IL, United States 62220

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5789399		19980804
APPLICATION INFO.:	US 1996-720698		19961002 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-5030	19951010 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Cintins, Marianne M.	
ASSISTANT EXAMINER:	Moezie, M.	
LEGAL REPRESENTATIVE:	Howell & Haferkamp, L.C.	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	739	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treating pruritus comprising topical administration of formulation of vitamin D or an analog of vitamin D is disclosed. The formulation comprises a therapeutically effective, water-based emulsion, water-based suspension or oil-based formulation of vitamin D or analog of vitamin D.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 18 MEDLINE

ACCESSION NUMBER: 1998286327 MEDLINE

DOCUMENT NUMBER: 98286327 PubMed ID: 9623124

TITLE: [Adverse effects of sunlight on the skin].
Nadelige effecten van zonlicht op de huid.

AUTHOR: de Gruijl F R

CORPORATE SOURCE: Academisch Ziekenhuis, afd. Dermatologic/Allergologie, Utrecht.

SOURCE: NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE, (1998 Mar 21) 142 (12) 620-5. Ref: 22
Journal code: NUK; 0400770. ISSN: 0028-2162.

PUB. COUNTRY: Netherlands
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)

LANGUAGE: Dutch

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199807

ENTRY DATE: Entered STN: 19980811

Last Updated on STN: 19980811

Entered Medline: 19980724

AB Many people consider a summer's day pleasant: warm and bright. The sun's ultraviolet rays do not contribute to the pleasure, and are biologically mainly harmful. As UV radiation does not penetrate any deeper than our skin, this organ has to be particularly well adapted to the UV exposure. The skin exploits the UV radiation for the synthesis of vitamin D3. Our day-to-day exposure suffices for this beneficial UV effect. Excessive exposure, as in sunbathing, only contributes to the adverse effects, like **sunburn** and suppression of cellular immunity in the short term, and 'photoaging' and skin cancer in the long term. The UVB radiation in sunlight is mainly responsible for these harmful effects, the UVA radiation to a far lesser extent (10-20% contribution). The UVA radiation from modern tanning equipment does not differ from that in sunlight, but UVA radiation does not lead to vitamin D3 production; it rather degrades vitamin D3 and a tan offers insufficient protection against the UVB radiation in full sunlight.

L5 ANSWER 8 OF 18 BIOSIS COPYRIGHT 2002 BIOSIS

ACCESSION NUMBER: 1994:459007 BIOSIS

DOCUMENT NUMBER: PREV199497472007

TITLE: The molecular and cellular pathology of solar ultraviolet radiation.

AUTHOR(S): Tyrrell, R. M.

CORPORATE SOURCE: ISREC, Swiss Inst. Exp. Cancer Res., Chemin Bioveresses 155, 1066 Epalinges Switzerland

SOURCE: Molecular Aspects of Medicine, (1994) Vol. 15, No. 1, pp. 1-77.

ISSN: 0098-2997.

DOCUMENT TYPE: General Review

LANGUAGE: English

L5 ANSWER 9 OF 18 BIOSIS COPYRIGHT 2002 BIOSIS

ACCESSION NUMBER: 1993:337009 BIOSIS

DOCUMENT NUMBER: PREV199345031734

TITLE: Protective effect of 1-alpha,25-dihydroxyvitamin D-3 against UVB injury: Possible role of the vitamin D-3-induced metallothionein.

AUTHOR(S): Hanada, K.; Sugawara, T.; Ohishi, Y.; Hashimoto, I.

CORPORATE SOURCE: Dep. Dermatol., Hirosaki Univ. Sch. Med., Hirosaki 036 Japan

SOURCE: Shima, A. [Editor]; Ichahashi, M. [Editor]; Fujiwara, Y. [Editor]; Takebe, H. [Editor]. International Congress Series, (1993) No. 1021, pp. 479-482. International Congress Series; Frontiers of photobiology. Publisher: Excerpta Medica 305 Keizersgracht, PO Box 1126, Amsterdam, Netherlands. Meeting Info.: 11th International Congress on Photobiology Kyoto, Japan September 7-12, 1992

ISSN: 0531-5131. ISBN: 0-444-89721-6.

DOCUMENT TYPE: Article

LANGUAGE: English

L5 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:72499 CAPLUS

DOCUMENT NUMBER: 120:72499

TITLE: Suntanning bed radiation increases vitamin D synthesis in human skin in vivo

AUTHOR(S): Shao, Q.; Chen, T. C.; Holick, M. F.

CORPORATE SOURCE: Sch. Med., Boston Univ., Boston, MA, 02118, USA

SOURCE: Biol. Eff. Light, Proc. Symp. (1992), Meeting Date 1991, 62-6. Editor(s): Holick, Michael F.; Kligman, Albert M. de Gruyter: Berlin, Germany.

CODEN: 59NRA6

DOCUMENT TYPE: Conference
LANGUAGE: English

AB A short period of exposure to suntanning beds can be utilized to generated sufficient amts. of vitamin D3 in vivo. Thus, suntanning bed radiation may be an effective and pleasant method to eliminate vitamin D deficiency, esp. for those who live in areas where the synthesis of vitamin D by natural sunlight is limited in winter.

L5 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:72462 CAPLUS

DOCUMENT NUMBER: 120:72462

TITLE: Evaluation of the effect of suntanning bed radiation on the synthesis of previtamin D3 and the degradation of vitamin D3 in an in vitro model

AUTHOR(S): Chen, T. C.; Lu, Z.; Holick, M. F.

CORPORATE SOURCE: Sch. Med., Boston Univ., Boston, MA, 02118, USA

SOURCE: Biol. Eff. Light, Proc. Symp. (1992), Meeting Date 1991, 57-61. Editor(s): Holick, Michael F.; Kligman, Albert M. de Gruyter: Berlin, Germany.

CODEN: 59NRA6

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Judicious exposure to suntanning bed radiation may be useful not only for tanning purposes, but also for the cutaneous prodn. of vitamin D3, esp. for the elderly who live in locations where the synthesis of vitamin D by natural sunlight is limited during the winter.

L5 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2002 ACS

DUPLICATE 1

ACCESSION NUMBER: 1991:542010 CAPLUS

DOCUMENT NUMBER: 115:142010

TITLE: Retinol skin care composition

INVENTOR(S): Katzev, Phillip K.

PATENT ASSIGNEE(S): USA

SOURCE: U.S., 4 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5002760	A	19910326	US 1989-415709	19891002

AB A skin care compn. for prevention of premature photoaging comprises retinol 0.01-0.1, UV absorbers 2-20, humectants 0.9-3.5, waxes and oils 2.0-5.8, emulsifiers 0.4-2.0, preservatives 0.1-0.6, softeners 0.7-2.7, conditioners 2-10, perfumes 0.05-0.5, hydrolyzed collagen 0.05-0.2, vitamins 0.04-0.4, and water 75-85%. The combination of retinol, UV absorber, and moisturizer potentiates the desirable activity of retinol, furthermore, the oils and conditioners allow better penetration of retinol to the lower layers of skin. A skin prepn. contained hydrolyzed collagen 0.149, methylparaben 0.1865, propylparaben 0.13, stearyl amidopropyldimethylamine lactate 3.576, dimethyldistearylammonium chloride 2.686, steryl wax 0.93, cetyl wax 0.93, pola wax 0.93, glycerin 0.6215, coconut oil 0.6215, allantoin 1.258, urea 0.42, squalene 0.298, apricot oil 0.075, avocado oil 0.075, olive oil 0.075, sesame oil 0.075, octyl methoxycinnamate 5.0, vitamin A 0.037, vitamin D3 0.037, pantothenol 0.037, aloe vera 0.746, lavender 0.234, retinol 0.039, Na pyrrolidonecarboxylic acid 0.0789, NaCl 0.326, and water 79.68%.

L5 ANSWER 13 OF 18 MEDLINE

ACCESSION NUMBER: 91246657 MEDLINE
 DOCUMENT NUMBER: 91246657 PubMed ID: 1645473
 TITLE: Solar ultraviolet radiation effects on biological systems.
 AUTHOR: Diffey B L
 CORPORATE SOURCE: Regional Medical Physics Department, Dryburn Hospital,
 Durham, UK.
 SOURCE: PHYSICS IN MEDICINE AND BIOLOGY, (1991 Mar) 36 (3) 299-328.
 Ref: 164
 Journal code: P6J; 0401220. ISSN: 0031-9155.
 PUB. COUNTRY: ENGLAND: United Kingdom
 Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, ACADEMIC)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 199107
 ENTRY DATE: Entered STN: 19910719
 Last Updated on STN: 19910719
 Entered Medline: 19910703

← L5 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:538336 CAPLUS
 DOCUMENT NUMBER: 113:138336
 TITLE: Tanning skin cosmetics containing vitamin D3
 derivatives
 INVENTOR(S): Shinomya, Tatsuro; Ogawa, Tadatake
 PATENT ASSIGNEE(S): Kanebo, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02178218	A2	19900711	JP 1988-332202	19881227

AB Tanning cosmetics contain vitamin D3 and/or its derivs. Propylene glycol 3.0, glycerin 5.0, methylparaben 0.1, poly(oxyethylene) hydrogenated castor oil 0.5, EtOH 5.0, cholecalciferol 0.1, and H2O to 100% by wt. were mixed to give a lotion, which showed good tanning effect without damaging the skin.

L5 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:568123 CAPLUS
 DOCUMENT NUMBER: 113:168123
 TITLE: Suntanning and cutaneous synthesis of vitamin D3
 AUTHOR(S): Matsuoka, Lois Y.; Wortsman, Jacobo; Hollis, Bruce W.
 CORPORATE SOURCE: Dep. Dermatol., Jefferson Med. Coll., Philadelphia, PA, 19107, USA
 SOURCE: J. Lab. Clin. Med. (1990), 116(1), 87-90
 CODEN: JLCMAK; ISSN: 0022-2143
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Skin tanning is the melanization of the epidermis induced by excessive sunlight exposure. Since melanin absorbs preferentially the wavelengths around 300 nm and the cutaneous synthesis of vitamin D3 is stimulated by the same wavelengths (290-320 nm, UV light B), the effect of tanning was investigated on vitamin D3 formation. Vitamin D3 and 25-hydroxyvitamin D (25-OH-D) serum levels were measured during midwinter (untanned state) in healthy subjects. Blood was obtained immediately before whole-body exposure to UVB in a phototherapy unit, and again 24 h later. The study

was repeated in the same subjects during midsummer (tanned state) using the same UVB dose. Serum vitamin D3 increased in the untanned state from 1.7 ng/mL to 11 ng/mL following UVB. In the tanned state, basal serum vitamin D3 was higher in the basal state (9.6 ng/mL) and exhibited an insignificant increase after UVB to 14.3 ng/mL. Tanning was also assocd. with higher serum 25-OH-D levels, i.e., 22.5 ng/mL (untanned) vs. 36.9 ng/mL (tanned). Thus, excessive solar exposure produces, besides erythema and tanning, resetting of the vitamin D3 synthetic mechanism with blunting of the response to UVB.

~ L5 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1990:558449 CAPLUS
 DOCUMENT NUMBER: 113:158449
 TITLE: Cosmetic skin preparations containing palmitic acid and/or stearic acid and vitamin D3 derivatives for suntanning
 INVENTOR(S): Ando, Hideya; Hashimoto, Akira; Tanigaki, Noriko; Kanehisa, Shusuke
 PATENT ASSIGNEE(S): Sunstar, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01249714	A2	19891005	JP 1988-77030	19880330

AB Cosmetic skin preps. contain .gtoreq.1 compd. chosen from palmitic acid (I) and stearic acid and .gtoreq.1 compd. chosen from 7-dehydrocholesterol, cholecalciferol (II), 25-hydroxycholecalciferol, 1.alpha.-hydroxycholecalciferol, 1.alpha.,25-dihydroxycholecalciferol, 5,6-trans-25-hydroxycholecalciferol, and dihydrotachysterol. The carboxylic acids and the vitamin D3 derivs. show synergistic suntanning effect without damaging the skin. A skin prep. comprised II 0.5, I 5.0, glycerin 6.0, EtOH 8.0, ethoxylated hydrogenated castor oil 0.8, citric acid 0.05, Na citrate 0.07, perfume 0.1, and H2O to 100% by wt.

L5 ANSWER 17 OF 18 MEDLINE

ACCESSION NUMBER: 89378393 MEDLINE
 DOCUMENT NUMBER: 89378393 PubMed ID: 2550287
 TITLE: Mechanisms for hyperpigmentation in postinflammatory pigmentation, urticaria pigmentosa and **sunburn**.
 AUTHOR: Tomita Y; Maeda K; Tagami H
 CORPORATE SOURCE: Department of Dermatology, Tohoku University School of Medicine, Sendai, Japan.
 SOURCE: DERMATOLOGICA, (1989) 179 Suppl 1 49-53.
 Journal code: E3D; 0211607. ISSN: 0011-9075.
 PUB. COUNTRY: Switzerland
 Journal; Article; (JOURNAL ARTICLE)
 LANGUAGE: English
 FILE SEGMENT: Priority Journals
 ENTRY MONTH: 198910
 ENTRY DATE: Entered STN: 19900309
 Last Updated on STN: 19900309
 Entered Medline: 19891023

AB Our in vitro studies demonstrate that normal human epidermal melanocytes become swollen and more dendritic with an increase in amount of immunoreactive tyrosinase when they are cultured for several days with arachidonic acid metabolites, vitamin D3 or histamine. From these data we propose the following possible mechanisms for hyperpigmentations noted at

postinflammatory sites and suntanned areas as well as at skin lesions of urticaria pigmentosa. Arachidonic acid metabolites and histamine, which are found in increased amounts in inflammatory skin, are thought to play a key role in the induction of postinflammatory hyperpigmentation. In sunburnt skin the increased proinflammatory mediators, particularly arachidonic acid metabolites, are also thought to stimulate melanocytes in the production of hyperpigmentation. Thus tanning after sun exposure may be induced not only by the effect of vitamin D3 and direct UV irradiation on the melanocytes but also by the effect of various arachidonic acid metabolites which are increased in sunburnt skin. Mast cells massively proliferate in the skin lesions of urticaria pigmentosa. Thus hyperpigmentation in the skin lesions of urticaria pigmentosa is quite likely to be induced by the chemical mediators, including histamine and leukotrienes, that are released from these cells.

L5 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1987:428191 CAPLUS

DOCUMENT NUMBER: 107:28191

TITLE: Sunscreens suppress cutaneous vitamin D3 synthesis

AUTHOR(S): Matsuoka, Lois Y.; Ide, Lorraine; Wortsman, Jacobo; MacLaughlin, Julia A.; Holick, Michael F.

CORPORATE SOURCE: Sch. Med., South. Illinois Univ., Springfield, IL, 62708, USA

SOURCE: J. Clin. Endocrinol. Metab. (1987), 64(6), 1165-8

CODEN: JCEMAZ; ISSN: 0021-972X

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Sunscreen agents interfered with the cutaneous prodn. of vitamin D3. The mean serum vitamin D3 concn. increased from 1.5 to 25.6 ng/mL in unprotected subjects, whereas it was 5.6 and 4.4 ng/mL in the same subjects who were protected with PABA. PABA also prevented the photoisomerization of 7-dehydrocholesterol to previtamin D3 in human skin slices in vitro. Thus, elderly chronic users of sunscreens should be routinely examd. for vitamin D deficiency.

=> d his

(FILE 'HOME' ENTERED AT 09:42:47 ON 09 JAN 2002)

FILE 'REGISTRY' ENTERED AT 09:43:20 ON 09 JAN 2002

. E CHOLECALCIFEROL/CN

L1 1 S E3

FILE 'MEDLINE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 09:44:48 ON 09 JAN 2002

L2 7452 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT?

L3 372928 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT? OR ULTRAVIOLET

L4 19 S L2 AND L1

L5 18 DUP REM L4 (1 DUPLICATE REMOVED)

L6 5 S (SUN(W)BURN OR SUNBURN) AND RADIATION(W)DERMATIT?

L7 4 DUP REM L6 (1 DUPLICATE REMOVED)

L8 720 S SUNBURN AND DERMATITIS

L9 228 S L8 AND ULTRAVIOLET

L10 219 DUP REM L9 (9 DUPLICATES REMOVED)

L11 46 S L10 AND ANTIOXIDANT

L11 ANSWER 1 OF 46 MEDLINE

ACCESSION NUMBER: 1998026983 MEDLINE
DOCUMENT NUMBER: 98026983 PubMed ID: 9361129
TITLE: Topical or oral administration with an extract of
Polypodium leucotomos prevents acute **sunburn** and
psoralen-induced phototoxic reactions as well as depletion
of Langerhans cells in human skin.
AUTHOR: Gonzalez S; Pathak M A; Cuevas J; Villarrubia V G;
Fitzpatrick T B
CORPORATE SOURCE: Department of Dermatology, Massachusetts General Hospital,
Boston 02114, USA.
SOURCE: PHOTODERMATOLOGY, PHOTOIMMUNOLOGY AND PHOTOMEDICINE, (1997
Feb-Apr) 13 (1-2) 50-60.
Journal code: AWP; 9013641. ISSN: 0905-4383.
PUB. COUNTRY: Denmark
(CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199801
ENTRY DATE: Entered STN: 19980129
Last Updated on STN: 19980129
Entered Medline: 19980112

AB **Sunburn**, immune suppression, photoaging, and skin cancers result from uncontrolled overexposure of human skin to solar **ultraviolet** radiation (UVR). Preventive measures, including photoprotection, are helpful and can be achieved by topical sunscreens agents. Polypodium leucotomos (PL) has been used for the treatment of inflammatory diseases and has shown some in vitro and in vivo immunomodulating properties. Its beneficial photoprotective effects in the treatment of vitiligo and its **antioxidant** properties encouraged us to evaluate in vivo the potentially useful photoprotective property of natural extract of PL after topical application or oral ingestion. Twenty-one healthy volunteers [either untreated or treated with oral psoralens (8-MOP or 5-MOP)] were enrolled in this study and exposed to solar radiation for evaluation of the following clinical parameters: immediate pigment darkening (IPD), minimal erythema dose (MED), minimal melanogenic dose (MMD), and minimal phototoxic dose (MPD) before and after topical or oral administration of PL. Immunohistochemical assessment of CD1a-expressing epidermal cells were also performed. PL was found to be photoprotective after topical application as well as oral administration. PL increased UV dose required for IPD ($P < 0.01$), MED ($P < 0.001$) and MPD ($P < 0.001$). After oral administration of PL, MED increased 2.8 ± 0.59 times and MPD increased 2.75 ± 0.5 and 6.8 ± 1.3 times depending upon the type of psoralen used. Immunohistochemical study revealed photoprotection of Langerhans cells by oral as well as topical PL. The observed photoprotective activities of oral or topical PL reveal a new avenue in examining the potentially useful field of systemic photoprotection and suggests that PL can be used as adjunct treatment and can make photochemotherapy and phototherapy possibly safe and effective when the control of cutaneous phototoxicity to PUVA or UVB is a limiting factor in such phototherapies.

L11 ANSWER 2 OF 46 USPATFULL

ACCESSION NUMBER: 2002:5752 USPATFULL
TITLE: Method for enhancing protective cellular responses to
genotoxic stress in skin
INVENTOR(S): Jacobson, Elaine L., Lexington, KY, United States
Jacobson, Myron K., Lexington, KY, United States
PATENT ASSIGNEE(S): University of Kentucky Research Foundation, Lexington,
KY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6337065	B1	20020108
APPLICATION INFO.:	US 1999-452617		19991201 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110482	19981201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose G.	
ASSISTANT EXAMINER:	Lamm, Marina	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski, LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 16 Drawing Page(s)	
LINE COUNT:	1377	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to methods of using pro-NAD agents capable of enhancing the dermal and epidermal skin cell NAD content. These pro-NAD agents may be administered topically, orally, or parenterally to enhance DNA repair and other protective responses to DNA damage. The invention further relates to pharmaceutical compositions comprising pro-NAD agents that effectively elevate intracellular NAD content. Finally, the invention relates to the method of using the pro-NAD agents to treat disorders such as **sunburn** and other skin deterioration that results from DNA damage in skin cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 3 OF 46 USPATFULL

ACCESSION NUMBER: 2002:4316 USPATFULL
 TITLE: Cytoprotective Compounds
 INVENTOR(S): Franson, Richard C., Richmond, VA, UNITED STATES
 Ottenbrite, Raphael M., Midlothian, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002002296	A1	20020103
APPLICATION INFO.:	US 2000-481824	A1	20000112 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-17511, filed on 2 Feb 1998, GRANTED, Pat. No. US 6020510 Continuation of Ser. No. US 1996-632030, filed on 15 Apr 1996, GRANTED, Pat. No. US 5859271		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	JOHN S. PRATT, KILPATRICK STOCKTON LLP, 1100 PEACHTREE, SUITE 2800, ATLANTA, GA, 30309		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1812		

AB The present invention provides compositions and methods for protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents. Even more particularly, the present invention provides compositions and methods for treating or prophylactically inhibiting phospholipase mediated injury, injury due to oxidation, and inflammation. In a very specific sense, this invention provides compositions and methods of making these compositions that are inhibitors of phospholipase.

L11 ANSWER 4 OF 46 USPATFULL

ACCESSION NUMBER: 2001:188218 USPATFULL
TITLE: Method for enhancing protective cellular responses to
genotoxic stress in skin
INVENTOR(S): Jacobson, Elaine L., Lexington, KY, United States
Jacobson, Myron K., Lexington, KY, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001033848	A1	20011025
APPLICATION INFO.:	US 2001-765129	A1	20010118 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-452617, filed on 1 Dec 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-110482	19981201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Page(s)	
LINE COUNT:	1491	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to methods of using pro-NAD agents capable of enhancing the dermal and epidermal skin cell NAD content. These pro-NAD agents may be administered topically, orally, or parenterally to enhance DNA repair and other protective responses to DNA damage. The invention further relates to pharmaceutical compositions comprising pro-NAD agents that effectively elevate intracellular NAD content. Finally, the invention relates to the method of using the pro-NAD agents to treat disorders such as **sunburn** and other skin deterioration that results from DNA damage in skin cells.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 46 USPATFULL

ACCESSION NUMBER: 2001:102409 USPATFULL
TITLE: Nutraceutical composition for protection against solar radiation
INVENTOR(S): Bragaglia, Anthony Joseph, Boston, MA, United States
PATENT ASSIGNEE(S): Protective Factors, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6254898	B1	20010703
APPLICATION INFO.:	US 2000-578596		20000525 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Tate, Christopher R.		
ASSISTANT EXAMINER:	Flood, Michele		
LEGAL REPRESENTATIVE:	Mueller and Smith, LPA		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	501		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A nutraceutical composition, for the inhibition of photochemical damage to the skin and eyes induced by sunlight, particularly by exposure to

ultraviolet radiation is disclosed. The blend is multifunctional and comprises a blend of chemopreventive natural products, which exert anti-radical mechanisms of prevention and intervention, anti-inflammatory effects, enhance the endogenous defense mechanisms, and also have the potential to reduce the radiation induced pigmentation. The active ingredients in the blend include green tea extract, lutein (zeaxanthin), lipoic acid, and selenomethionine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 46 USPATFULL

ACCESSION NUMBER: 2001:93556 USPATFULL
TITLE: Treatment of inflammation with 2,4,6-trihydroxy-alpha-rho-methoxyphenylacetophenone, or its pharmaceutically acceptable derivatives
INVENTOR(S): Uckun, Fatih M., White Bear Lake, MN, United States
Malaviya, Ravi, St. Paul, MN, United States
PATENT ASSIGNEE(S): Parker Hughes Institute, Roseville, MN, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6248790	B1	20010619
APPLICATION INFO.:	US 2000-606926		20000629 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Henley, III, Raymond		
LEGAL REPRESENTATIVE:	Mechant & Gould P.C.		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1028		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB 2,4,6-trihydroxy-.alpha.-p-methoxyphenylacetophenone (also identified herein as "D-58"), or its pharmaceutically acceptable derivatives such as salt and ester forms, is administered for inhibiting inflammatory reactions. The treatment can be remedial or prophylactic. Examples of the conditions that can be treated include acute inflammatory reactions and allergic inflammatory reactions, and specific examples include allergy, asthma, arthritis, psoriasis, skin **sunburn**, inflammatory pelvic disease, inflammatory bowel disease, urethritis, uveitis, sinusitis, pneumonitis, encephalitis, meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis, gastritis, enteritis, **dermatitis**, gingivitis, appendicitis, pancreatitis, cholecystitis and cholangitis. The 2,4,6-trihydroxy-.alpha.-p-methoxyphenylacetophenone can be administered by various routes as needed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 46 USPATFULL

ACCESSION NUMBER: 2000:125020 USPATFULL
TITLE: Treatment of skin with a formulation comprising alpha-glucosyl rutin and one or more cinnamic acid derivatives
INVENTOR(S): Lanzendorfer, Ghita, Hamburg, Germany, Federal Republic of
Stab, Franz, Echem, Germany, Federal Republic of
Untiedt, Sven, Hamburg, Germany, Federal Republic of
PATENT ASSIGNEE(S): Beiersdorf AG, Hamburg, Germany, Federal Republic of
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121243		20000919
	WO 9618379		19960620
APPLICATION INFO.:	US 1997-849524		19970908 (8)
	WO 1995-EP4905		19951212
			19970908 PCT 371 date
			19970908 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4444238	19941213
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Cook, Rebecca	
LEGAL REPRESENTATIVE:	Norris, McLaughlin & Marcus, P.A.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1046	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for treatment of prophylaxis of skin against ageing, against inflammation and for protection from photoreaction and oxidative influences which comprise applying a formulation comprising alpha-glucosyl rutin and one or more cinnamic acid derivatives to the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 46 USPATFULL

ACCESSION NUMBER: 2000:87621 USPATFULL

TITLE: Medical uses of pyruvates

INVENTOR(S): Brunengraber, Henri, Shaker Heights, OH, United States
Bomont, Catherine, Scotch Plains, NJ, United States
David, France, Shaker Heights, OH, United States
Hallowell, Peter T., Cleveland Heights, OH, United States
Cooper, Kevin D., Moreland Hills, OH, United States
Kasoumov, Takhar, Cleveland, OH, United States

PATENT ASSIGNEE(S): Case Western Reserve University, Cleveland, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6086789		20000711
APPLICATION INFO.:	US 1998-76374		19980512 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-807585, filed on 27 Feb 1997, now patented, Pat. No. US 5876916 which is a continuation-in-part of Ser. No. US 1996-617285, filed on 18 Mar 1996, now patented, Pat. No. US 5667962		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46343	19970513 (60)
	US 1998-80695	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	McKane, Joseph	
ASSISTANT EXAMINER:	Oswecki, Jane C.	
LEGAL REPRESENTATIVE:	Fay, Sharpe, Fagan, Minnich & McKee, LLP	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 17 Drawing Page(s)	

LINE COUNT: 1499

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pyruvate compound suitable for cosmetically or dermatologically administering to the skin and for use in treating diabetic ketosis or other medical treatments. The compound includes a pyruvate selected from the group of pyruvate thioester, dihydroxyacetonepyruvate, and an ester of pyruvate and a sugar or a polyol.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 46 USPATFULL

ACCESSION NUMBER: 2000:15323 USPATFULL

TITLE: Rinse-off water-in-oil-in-water compositions

INVENTOR(S): Herb, Craig A., Chicago, IL, United States

Chen, Liang Bin, Lombard, IL, United States

Chung, Judy, Glenview, IL, United States

Long, Michelle A., Lombard, IL, United States

Sun, Wei Mei, Palatine, IL, United States

Newell, Gerald P., Hoffman Estates, IL, United States

Evans, Trefor A., Lombard, IL, United States

Kamis, Kimberly, Glenview, IL, United States

Brucks, Richard M., Chicago, IL, United States

PATENT ASSIGNEE(S): Helene Curtis, Inc., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION:	US 6022547		20000208
---------------------	------------	--	----------

APPLICATION INFO.:	US 1996-670853		19960628 (8)
--------------------	----------------	--	--------------

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-349963, filed on 6 Dec 1994, now patented, Pat. No. US 5589177		
-----------------------	-------------------------------------------------------------------------------------------------	--	--

DOCUMENT TYPE:	Utility		
----------------	---------	--	--

FILE SEGMENT:	Granted		
---------------	---------	--	--

PRIMARY EXAMINER:	Harrison, Robert H.		
-------------------	---------------------	--	--

LEGAL REPRESENTATIVE:	Boxer, Matthew		
-----------------------	----------------	--	--

NUMBER OF CLAIMS:	56		
-------------------	----	--	--

EXEMPLARY CLAIM:	1		
------------------	---	--	--

LINE COUNT:	2952		
-------------	------	--	--

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Rinse-off, water-in-oil-in-water multiple emulsion compositions are disclosed. The multiple emulsion compositions comprise an external aqueous phase optionally incorporating an emulsifier and/or a second topically-active compound. The internal phase comprises a primary water-in-oil emulsion, wherein the primary emulsion comprises a first topically-active compound, a surfactant phase, an oil phase, and water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 10 OF 46 USPATFULL

ACCESSION NUMBER: 2000:12973 USPATFULL

TITLE: Cytoprotective compounds

INVENTOR(S): Franson, Richard C., Richmond, VA, United States

Ottenbrite, Raphael M., Midlothian, VA, United States

PATENT ASSIGNEE(S): Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION:	US 6020510		20000201
---------------------	------------	--	----------

APPLICATION INFO.:	US 1998-17511		19980202 (9)
--------------------	---------------	--	--------------

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-632030, filed on 15 Apr 1996, now patented, Pat. No. US 5859271		
-----------------------	--------------------------------------------------------------------------------------------------	--	--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Reamer, James H.
LEGAL REPRESENTATIVE: Jones & Askew LLP
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 1891

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents. Even more particularly, the present invention provides compositions and methods for treating or prophylactically inhibiting phospholipase mediated injury, injury due to oxidation, and inflammation. In a very specific sense, this invention provides compositions and methods of making these compositions that are inhibitors of phospholipase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 11 OF 46 USPATFULL

ACCESSION NUMBER: 2000:1910 USPATFULL

TITLE: **Antioxidant** composition for the treatment of psoriasis and related diseases

INVENTOR(S): Hersh, Theodore, Atlanta, GA, United States

PATENT ASSIGNEE(S): Thione International, Inc., Atlanta, GA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6011067		20000104
APPLICATION INFO.:	US 1999-329849		19990611 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	MacMillan, Keith D.		
ASSISTANT EXAMINER:	Kim, Vickie		
LEGAL REPRESENTATIVE:	Wittenberg, Malcolm B.		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
LINE COUNT:	785		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention deals with the combination of several synergistic antioxidants including enzymatic co-factors as adjuncts to therapy of desquamating inflammatory disorders, such as psoriasis. These topical compositions are aimed to neutralize free radical species generated by such inflammatory conditions which are responsible for certain clinical signs and symptoms. As such, damage to skin causing destruction of elastin and collagen tissues is reduced. The present synergistic antioxidants may be combined with anti-inflammatories, including corticosteroids, anti-microbials, including zinc pyrithione, and other preparations useful in the therapy of desquamating disorders as psoriasis, seborrheic **dermatitis** and related skin and scalp conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 12 OF 46 USPATFULL

ACCESSION NUMBER: 1999:142013 USPATFULL

TITLE: Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same

INVENTOR(S): Martin, Alain, Ringoes, NJ, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5981606		19991109
APPLICATION INFO.:	US 1998-19316		19980205 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned And a continuation of Ser. No. US 1994-224936, filed on 8 Apr 1994, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-37730	19970202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Barish, Jean B.	
NUMBER OF CLAIMS:	33	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	3528	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapeutic TGF-beta-wound healing compositions for reducing the formation of scar tissue and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), the therapeutic wound healing composition comprises (a) an **antioxidant** and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.D), the therapeutic wound healing composition comprises (a) lactate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In Embodiment Two (II), the therapeutic wound healing compositions of Embodiment One (I.A-D) are combined with a therapeutically effective amount of a TGF-beta (GF) to form TGF-beta-wound healing compositions (II.A-D+GF). This invention also pertains to methods for preparing and using the TGF-beta-wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 13 OF 46 USPATFULL

ACCESSION NUMBER: 1999:99364 USPATFULL
 TITLE: Water-in-oil-in-water compositions
 INVENTOR(S): Herb, Craig A., Chicago, IL, United States
 Chen, Liang Bin, Lombard, IL, United States
 Chung, Judy B., Glenview, IL, United States
 Long, Michelle A., Lombard, IL, United States
 Sun, Wei Mei, Palatine, IL, United States
 PATENT ASSIGNEE(S): Helene Curtis, Inc., Chicago, IL, United States (U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 5942216 19990824
APPLICATION INFO.: US 1997-804365 19970221 (8)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-349904, filed on 6 Dec
1994, now patented, Pat. No. US 5565280, issued on 12
Aug 1997
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Boxer, Matthew
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
LINE COUNT: 2750

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Water-in-oil-in-water multiple emulsion compositions are disclosed. The multiple emulsion compositions comprise an external aqueous phase optionally incorporating a surfactant system capable of forming liquid crystals as an emulsifier. The internal phase comprises a primary water-in-oil emulsion, wherein the primary emulsion comprises a first topically-active compound, a surfactant phase, an oil phase, and water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 14 OF 46 USPATFULL

ACCESSION NUMBER: 1999:27204 USPATFULL
TITLE: Use of salicin as an anti-irritative active compound in
cosmetic and topical dermatological preparations
INVENTOR(S): Schonrock, Uwe, Nahe, Germany, Federal Republic of
Steckel, Friedhelm, Hamburg, Germany, Federal Republic
of
Kux, Ulrich, Urayasu City, Japan
Inoue, Kazuo, Naka-Ku, Japan
PATENT ASSIGNEE(S): Beiersdorf AG, Hamburg, Germany, Federal Republic of
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5876737		19990302
APPLICATION INFO.:	US 1997-839619		19970415 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1996-19615577	19960419
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Richter, Johann	
ASSISTANT EXAMINER:	Howard, Sharon	
LEGAL REPRESENTATIVE:	Sprung Kramer Schaefer & Briscoe	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	831	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of salicin for the cosmetic or dermatological treatment and/or prophylaxis of irritant and/or erythematous skin symptoms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 15 OF 46 USPATFULL

ACCESSION NUMBER: 1999:24697 USPATFULL
TITLE: Therapeutic permeation enhanced-wound healing
compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5874479		19990223
APPLICATION INFO.:	US 1998-19457		19980205
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224936, filed on 8 Apr 1994, now abandoned And Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-38830	19970206 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Criares, Theodore J.	
LEGAL REPRESENTATIVE:	Barish, Jean B.	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	3600	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapeutic permeation enhanced-wound healing compositions for enhancing the penetration of actives into membranes and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), the therapeutic wound healing composition comprises (a) an **antioxidant** and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.D), the therapeutic wound healing composition comprises (a) lactate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In Embodiment Two (II), the therapeutic wound healing compositions of Embodiment One (I.A-D) are combined with a therapeutically effective amount of a permeation enhancing agent (PE) to form permeation enhanced-wound healing compositions (II.A-D+PE). This invention also pertains to methods for preparing and using the permeation enhanced-wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 16 OF 46 USPATFULL

ACCESSION NUMBER:	1999:12947	USPATFULL
TITLE:	Antibacterial-wound healing compositions and methods for preparing and using same	
INVENTOR(S):	Martin, Alain, Ringoes, NJ, United States	
PATENT ASSIGNEE(S):	Warner Lambert Company, Morris Plains, NJ, United States (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863938		19990126

APPLICATION INFO.: US 1995-446963 19950522 (8)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-53922, filed
on 26 Apr 1993, now abandoned which is a continuation
of Ser. No. US 1991-663500, filed on 1 Mar 1991, now
abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
LEGAL REPRESENTATIVE: Barish, Jean B.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3289

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic antibacterial-wound healing compositions. The compositions comprise a therapeutically effective amount of an antibacterial agent and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic antibacterial-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic antibacterial-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 17 OF 46 USPATFULL

ACCESSION NUMBER: 1999:4922 USPATFULL
TITLE: Cytoprotective compounds
INVENTOR(S): Franson, Richard C., Richmond, VA, United States
Ottenbrite, Raphael M., Midlothian, VA, United States
PATENT ASSIGNEE(S): Virginia Commonwealth University, Richmond, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5859271		19990112
APPLICATION INFO.:	US 1996-632030		19960415 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Reamer, James H.		
LEGAL REPRESENTATIVE:	Jones & Askew, LLP		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1803		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents. Even more particularly, the present invention provides compositions and methods for treating or prophylactically inhibiting phospholipase mediated injury, injury due to oxidation, and inflammation. In a very specific sense, this invention provides compositions and methods of making these compositions that are inhibitors of phospholipase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 18 OF 46 USPATFULL

ACCESSION NUMBER: 1999:1695 USPATFULL
TITLE: Therapeutic antiviral-wound healing compositions and

INVENTOR(S): methods for preparing and using same
Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner Lambert Company, Morris Plains, NJ, United
States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856364		19990105
APPLICATION INFO.:	US 1995-410079		19950329 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-224936, filed on 8 Apr 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	30 Drawing Figure(s); 21 Drawing Page(s)		
LINE COUNT:	4610		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells (Embodiment One (I)). This invention also pertains to therapeutic antiviral-wound healing compositions for reducing viral titers and increasing the proliferation and resuscitation rate of mammalian cells (Embodiment Two (II)). In a first aspect of Embodiment One (I.A), the therapeutic wound healing composition comprises (a) pyruvate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In a second aspect of Embodiment One (I.B), the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In a third aspect of Embodiment One (I.C), the therapeutic wound healing composition comprises (a) an **antioxidant** and (b) a mixture of saturated and unsaturated fatty acids. In a fourth aspect of Embodiment One (I.D), the therapeutic wound healing composition comprises (a) lactate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In Embodiment Two (II), the therapeutic wound healing compositions of Embodiment One (I.A-D) are combined with a therapeutically effective amount of an antiviral agent (V) to form antiviral-wound healing compositions (II.A-D+V). This invention also pertains to methods for preparing and using the antiviral-wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 19 OF 46 USPATFULL
ACCESSION NUMBER: 1998:162004 USPATFULL
TITLE: Polyphenolic cosmetic composition
INVENTOR(S): Tanabe, Masayuki, Matsudo, Japan
Kanda, Tomomasa, Kashiwa, Japan
Yanagida, Akio, Tokyo, Japan
Shoji, Toshihiko, Nagareyama, Japan
PATENT ASSIGNEE(S): The Nikka Whisky Distilling Co., Ltd., Tokyo, Japan
(non-U.S. corporation)

NUMBER	KIND	DATE
-----	-----	-----

PATENT INFORMATION: US 5853728 19981229
APPLICATION INFO.: US 1996-773596 19961227 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1995-342603	19951228
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Mosley, Terressa	
LEGAL REPRESENTATIVE:	Armstrong, Westerman Hattori, McLeland & Naughton	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	428	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cosmetics are herein disclosed which contain a polyphenol derived from the fruits of Rosaceae, and the polyphenol is obtainable by purifying a pressed juice or an extract of the unripe fruits of the Rosaceae, for example, apples, pears or peaches. The cosmetics have many useful functions such as an **ultraviolet** light absorbing activity and a free radical erasing activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 20 OF 46 USPATFULL

ACCESSION NUMBER: 1998:150961 USPATFULL
TITLE: Methods and bicyclic polyamine compositions for the treatment of inflammation
INVENTOR(S): Bergeron, Jr., Raymond J., Gainesville, FL, United States
PATENT ASSIGNEE(S): University of Florida Research Foundation, Inc., Gainesville, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5843959		19981201
APPLICATION INFO.:	US 1997-820027		19970319 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Jarvis, William R. A.		
LEGAL REPRESENTATIVE:	Kerkam, Stowell, Kondracki & Clarke, P.C., Clarke, Dennis P.		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1074		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for treating inflammatory conditions wherein the active agent is a polyamine having the formula set forth below: ##STR1## or a salt thereof with a pharmaceutically acceptable acid wherein: R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may be the same or different and represent H, straight- or branched-chain alkyl, aryl, aryl alkyl or cycloalkyl of 1-12 carbon atoms;

a, b, c and d may be the same or different and are integers from 0 to 8, except that when a or c is zero, b or d is greater than or equal to 3 and when a or c is one, b or d is greater than or equal to 2; and

X, Y and Z may be the same or different; X and Z are integers from 0 to 10; and Y is an integer from 1 to 10, excluding the polyamine of the formula wherein a=b=c=d=2, X=Z=2 and Y=4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 21 OF 46 USPATFULL

ACCESSION NUMBER: 97:120278 USPATFULL
TITLE: Processed product for skin and hair treatment
INVENTOR(S): Dixon, Gary W., P.O. Box 5835, Kingsport, TN, United States 37663-0835

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5700457		19971223
APPLICATION INFO.:	US 1996-653151		19960524 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-377501, filed on 24 Jan 1995, now patented, Pat. No. US 5554361 which is a continuation-in-part of Ser. No. US 1994-184839, filed on 21 Jan 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kulkosky, Peter F.		
LEGAL REPRESENTATIVE:	Brown, M. Alex		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2337		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A processed product for hair and skin treatment, having binary and tertiary fluid phase levels prior to remixing and therapeutic use is disclosed. The invention discloses defined amounts of admixed components including an Iodine complex having tincture of iodine solution and povidone-iodine compound, a diluting fluid complex having a water and mineral oil constituent, and a cod liver oil component, which, after admixing, are ambiently exposed to a photon-light-energy component from sunlight or substantially equivalent artificial light to produce a processed product having at least binary product reaction fluid levels and containing a nucleophilically iodinated cod liver oil compound. The composition is mixed prior to therapeutic application of targeted hair, skin, mucosal or internal areas of a human or animal, mixing the fluid levels to provide synergistic properties and enhanced delivery of the remaining iodine-reaction components and the iodinated cod liver oil compound contained in the product, enhancing the effect and delivery to targeted areas of vitamins A and D and other constituents in the processed reaction product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 22 OF 46 USPATFULL

ACCESSION NUMBER: 97:111158 USPATFULL
TITLE: Razor cartridges comprising wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
Vreeland, William E., Shelton, CT, United States
Booth, Anthony R., Chester, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5692302		19971202
APPLICATION INFO.:	US 1995-447018		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-315734, filed on 30 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation		

of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Watts, Douglas D.
 LEGAL REPRESENTATIVE: Almer, Charles W., Barish, Jean B.
 NUMBER OF CLAIMS: 39
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 18 Drawing Figure(s); 16 Drawing Page(s)
 LINE COUNT: 3554

AB This invention pertains to therapeutic wound healing compositions useful for preventing and reducing injury to mammalian cells affixed to razor cartridges to form therapeutic razor cartridges with wound healing compositions. In one embodiment of this invention the therapeutic wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. This invention also pertains to methods for making and using the razor cartridges comprising therapeutic wound healing compositions.

L11 ANSWER 23 OF 46 USPATFULL

ACCESSION NUMBER: 97:91569 USPATFULL
 TITLE: Sunscreen-wound healing compositions and methods for preparing and using same
 INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
 PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5674912		19971007
APPLICATION INFO.:	US 1995-446979		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-350918, filed on 7 Dec 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		

DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Criares, Theodore J.
 LEGAL REPRESENTATIVE: Barish, Jean B.
 NUMBER OF CLAIMS: 28
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
 LINE COUNT: 3764

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to therapeutic sunscreen-wound healing compositions useful to minimize and treat **sunburn** damage. The compositions comprise a therapeutically effective amount of (1) a sunscreen agent; (2) an anti-inflammatory; and, (3) a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic sunscreen-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic sunscreen-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 24 OF 46 USPATFULL

ACCESSION NUMBER: 97:78477 USPATFULL

TITLE: Antifungal wound healing compositions and methods for preparing and using same

INVENTOR(S): Martin, Alain, Ringoes, NJ, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5663208		19970902
APPLICATION INFO.:	US 1995-445831		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-279462, filed on 22 Jul 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3384		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic antifungal-wound healing compositions. The compositions comprise a therapeutically effective amount of an antifungal agent and a wound healing compositions. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic antifungal-wound healing compositions may be utilized in a wide variety of topical and ingestible pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic antifungal-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 25 OF 46 USPATFULL

ACCESSION NUMBER: 97:73664 USPATFULL

TITLE: Immunostimulating wound healing compositions and method for preparing and using same

INVENTOR(S): Martin, Alain, Ringoes, NJ, United States

PATENT ASSIGNEE(S): Warner Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658957		19970819
APPLICATION INFO.:	US 1995-446986		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 23 Drawing Figure(s); 17 Drawing Page(s)

LINE COUNT: 3521

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic immunostimulating-wound healing compositions. The compositions comprise a therapeutically effective amount of an immunostimulating agent and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic immunostimulating-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic immunostimulating-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 26 OF 46 USPATFULL

ACCESSION NUMBER: 97:73663 USPATFULL

TITLE: Bioadhesive-wound healing compositions and methods for preparing and using same

INVENTOR(S): Martin, Alain, Ringoes, NJ, United States

Leung, Sau-Hung S., Parsippany, NJ, United States

PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658956		19970819
APPLICATION INFO.:	US 1995-445824		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-298521, filed on 30 Aug 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	90 Drawing Figure(s); 77 Drawing Page(s)		
LINE COUNT:	5895		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to therapeutic bioadhesive-wound healing compositions useful for treating wounds and increasing the proliferation and resuscitation rate of mammalian cells. The compositions comprise a bioadhesive agent and a therapeutically effective amount of a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic bioadhesive-wound healing compositions may further comprise medicaments such as antiviral agents, antikeratolytic agents, anti-inflammatory agents, antifungal agents, antibacterial agents, immunostimulating agents, and the like. The bioadhesive-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the bioadhesive-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 27 OF 46 USPATFULL

ACCESSION NUMBER: 97:73275 USPATFULL

TITLE: Cosmetic or dermatological preparations comprising hydrophobicized inorganic pigments for preserving the urocaninic acid state of the skin

INVENTOR(S): Gers-Barlag, Heinrich, Kummerfeld, Germany, Federal Republic of
Schulz, Sabine, Hamburg, Germany, Federal Republic of
Uhlmann, Beate, Hamburg, Germany, Federal Republic of
Hintze, Ulrich, Hamburg, Germany, Federal Republic of
Schmucker, Robert, Hamburg, Germany, Federal Republic of

PATENT ASSIGNEE(S): Beiersdorf Aktiengesellschaft, Hamburg, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5658556		19970819
APPLICATION INFO.:	US 1995-515759		19950815 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1994-4429468	19940819
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gardner, Salle M.	
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	882	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of one or more hydrophobicized, pharmaceutically or cosmetically acceptable inorganic pigments in cosmetic or dermatological preparations for preventing

leaching out or washing off of the skin's cis- or trans-urocaninic acid from the human skin, caused by the action of water, or

leaching out or washing off of cis- or trans-urocaninic acid which has been applied artificially to the skin, from the human skin caused by the action of water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 28 OF 46 USPATFULL

ACCESSION NUMBER: 97:70725 USPATFULL

TITLE: Water-in-oil-in-water compositions

INVENTOR(S): Herb, Craig A., Chicago, IL, United States
Chen, Liang Bin, Hoffman Estates, IL, United States
Chung, Judy, Glenview, IL, United States
Long, Michelle A., Lombard, IL, United States
Sun, Wei Mei, Palatine, IL, United States
Newell, Gerald P., Hoffman Estates, IL, United States
Evans, Trefor A., Lombard, IL, United States
Kamis, Kimberly, Glenview, IL, United States
Brucks, Richard M., Chicago, IL, United States
PATENT ASSIGNEE(S): Helene Curtis, Inc., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5656280		19970812

APPLICATION INFO.: US 1994-349904 19941206 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Lovering, Richard D.
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1,2,14
LINE COUNT: 2799

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Water-in-oil-in-water multiple emulsion compositions are disclosed. The multiple emulsion compositions comprise an external aqueous phase optionally incorporating a surfactant system capable of forming liquid crystals as an emulsifier. The internal phase comprises a primary water-in-oil emulsion, wherein the primary emulsion comprises a first topically-active compound, a surfactant phase, an oil phase, and water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 29 OF 46 USPATFULL

ACCESSION NUMBER: 97:66160 USPATFULL
TITLE: Therapeutic-wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, 31 Country Club Dr., Ringoes, NJ, United States 08551

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5652274		19970729
APPLICATION INFO.:	US 1995-445813		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-187435, filed on 27 Jan 1994, now abandoned which is a continuation of Ser. No. US 1991-798392, filed on 26 Nov 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	90 Drawing Figure(s); 77 Drawing Page(s)		
LINE COUNT:	9592		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic wound healing compositions for protecting and resuscitating mammalian cells. In one embodiment, the therapeutic wound healing composition comprises (a) pyruvate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. In another embodiment, the therapeutic wound healing composition comprises (a) pyruvate, (b) lactate, and (c) a mixture of saturated and unsaturated fatty acids. In yet another embodiment, the therapeutic wound healing composition comprises (a) an **antioxidant** and (b) a mixture of saturated and unsaturated fatty acids. In still yet another embodiment, the therapeutic wound healing composition comprises (a) lactate, (b) an **antioxidant**, and (c) a mixture of saturated and unsaturated fatty acids. This invention also pertains to wound healing compositions combined with a medicament which is useful for treating injured mammalian cells to form augmented wound healing compositions such as immunostimulating-wound healing compositions, antiviral-wound healing compositions, antikeratolytic-wound healing compositions, anti-inflammatory-wound healing compositions, antifungal-wound healing compositions, acne treating-wound healing compositions, sunscreen-wound healing compositions,

dermatological-wound healing compositions, antihistamine-wound healing compositions, antibacterial-wound healing compositions, and bioadhesive-wound healing compositions. This invention also pertains to wound healing compositions combined with a cytotoxic agent to form cytoprotective-wound healing compositions useful for protecting and reducing injury to mammalian cells and to razor cartridges comprising the wound healing compositions. This invention also pertains to methods for preparing and using the wound healing compositions and the topical and ingestible pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 30 OF 46 USPATFULL

ACCESSION NUMBER: 97:63767 USPATFULL
TITLE: Pharmaceutical compositions and methods
INVENTOR(S): Bockow, Barry I., 16122 8th Ave. SW., Seattle, WA,
United States 98166

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650157		19970722
APPLICATION INFO.:	US 1994-247682		19940322 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-53508, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-816833, filed on 30 Dec 1991, now abandoned which is a continuation of Ser. No. US 1990-545414, filed on 27 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-520026, filed on 7 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Phelan, D. Gabrielle		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1069		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Some otherwise desirable oil compositions derived from natural sources are characterized by an unpleasant odor. Fractions or combinations of such oils may also be so characterized. Stable, deodorized oils may be prepared by adding an amount of a deodorizing agent effective to substantially reduce the odor of the derived oil composition, fraction or combination thereof to that oil composition, fraction or combination. The pharmaceutical topical compositions of the present invention contain these stable, deodorized oil compositions and exhibit enhanced penetration properties and achieve enhanced patient response. The improved pharmaceutical compositions of the present invention may be used to manage pain and/or to treat the underlying ailments. Methods of making such topical pharmaceutical compositions are also discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 31 OF 46 USPATFULL

ACCESSION NUMBER: 97:61711 USPATFULL
TITLE: Anti-inflammatory wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 5648380 19970715
 APPLICATION INFO.: US 1995-445845 19950522 (8)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1994-268429, filed
 on 30 Jun 1994, now abandoned which is a
 continuation-in-part of Ser. No. US 1993-53922, filed
 on 26 Apr 1993, now abandoned which is a continuation
 of Ser. No. US 1991-663500, filed on 1 Mar 1991, now
 abandoned
 DOCUMENT TYPE: Utility
 FILE SEGMENT: Granted
 PRIMARY EXAMINER: Criares, Theodore J.
 LEGAL REPRESENTATIVE: Barish, Jean B.
 NUMBER OF CLAIMS: 20
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
 LINE COUNT: 3375

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic anti-inflammatory-wound healing
 compositions. The compositions comprise a therapeutically effective
 amount of one or more anti-inflammatory agents and a wound healing
 composition. In one embodiment the wound healing composition comprises
 (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of
 saturated and unsaturated fatty acids. The therapeutic
 anti-inflammatory-wound healing compositions may be utilized in a wide
 variety of topical and ingestible pharmaceutical products. This
 invention also relates to methods for preparing and using the
 therapeutic anti-inflammatory-wound healing compositions and the
 pharmaceutical products in which the therapeutic compositions may be
 used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 32 OF 46 USPATFULL

ACCESSION NUMBER: 97:59248 USPATFULL
 TITLE: Acne treating-wound healing compositions and methods
 for preparing and using same
 INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
 PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646190		19970708
APPLICATION INFO.:	US 1995-446988		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-340579, filed on 11 Nov 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3329		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic acne treating-wound healing
 compositions useful for the topical treatment of aene vulgaris. The

compositions comprise a therapeutically effective amount of tretinoin and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixtrite of saturated and unsaturated fatty acids. The therapeutic acne treating-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic acne treating-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used. This invention also relates to methods for employing the therapeutic ache treating-wound healing compositions to treat wrinkles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 33 OF 46 USPATFULL

ACCESSION NUMBER: 97:54264 USPATFULL
TITLE: Antikeratolytic-wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5641814		19970624
APPLICATION INFO.:	US 1995-445808		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-268772, filed on 30 Jun 1994, now abandoned which is a continuation of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3314		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic antikeratolytic-wound healing compositions. The compositions comprise a therapeutically effective amount of an antikeratolytic agent and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic antikeratolytic-wound healing compositions may be utilized in a wide variety of topical and ingestible pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic antikeratolytic-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 34 OF 46 USPATFULL

ACCESSION NUMBER: 97:45047 USPATFULL
TITLE: Cytoprotective wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5633285		19970527
APPLICATION INFO.:	US 1995-446962		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-312841, filed on 27 Sep 1994, now abandoned which is a continuation of Ser. No. US 1992-841342, filed on 25 Feb 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	62 Drawing Figure(s); 35 Drawing Page(s)		
LINE COUNT:	4208		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic cytoprotective-wound healing compositions. The compositions comprise a cytotoxic agent and a therapeutic wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. In another embodiment the wound healing composition comprises (a) pyruvate; and, (b) an **antioxidant**. The therapeutic cytoprotective-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic cytoprotective-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 35 OF 46 USPATFULL

ACCESSION NUMBER:	97:25074	USPATFULL
TITLE:	Antihistamine-wound healing compositions and methods for preparing and using same	
INVENTOR(S):	Martin, Alain, Ringoes, NJ, United States	
PATENT ASSIGNEE(S):	Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5614561		19970325
APPLICATION INFO.:	US 1995-446985		19950522 (8)
DISCLAIMER DATE:	20150522		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Esq., Jean B.		
NUMBER OF CLAIMS:	19		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Figure(s); 11 Drawing Page(s)		
LINE COUNT:	3248		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains to therapeutic antihistamine-wound healing compositions. The compositions comprise a therapeutically effective amount of one or more antihistamine agents and a wound healing composition. In one embodiment the wound healing composition comprises

(a) pyruvate; (b) an **antioxidant**; and (c) a mixture of saturated and unsaturated fatty acids. The therapeutic antihistamine-wound healing compositions may be utilized in a wide variety of pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic antihistamine-wound healing compositions and the pharmaceutical products in which the therapeutic compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 36 OF 46 USPATFULL

ACCESSION NUMBER: 97:24720 USPATFULL
TITLE: Polypodium extract as photoprotectant
INVENTOR(S): Pathak, Madhukar A., Belmont, MA, United States
Gonzalez, Salvador, Boston, MA, United States
Fitzpatrick, Thomas B., Weston, MA, United States
PATENT ASSIGNEE(S): Industrial Farmaceutica Cantabria, S.A., Madrid, Spain
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5614197		19970325
APPLICATION INFO.:	US 1995-388261		19950213 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Rollins, John W.		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1396		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new methods and products for use in photoprotection from **ultraviolet** radiation. The products include extracts from ferns of the genus Polypodium mixed in preparations for topical application and oral administration. The preparations have both photoprotective and **antioxidant** properties. The topical formulations may also include physical and/or chemical sunscreen agents and/or cosmetic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 37 OF 46 USPATFULL

ACCESSION NUMBER: 97:12521 USPATFULL
TITLE: Dermatological wound healing compositions and methods for preparing and using same
INVENTOR(S): Martin, Alain, Ringoes, NJ, United States
Nayak, Ammunje S., Great Meadows, NJ, United States
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5602183		19970211
APPLICATION INFO.:	US 1995-446964		19950522 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-53922, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-663500, filed on 1 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Barish, Jean B.		

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT: 3460

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to therapeutic dermatological-wound healing compositions useful to minimize and treat diaper **dermatitis**. The compositions comprise a therapeutically effective amount of a buffering agent to maintain the pH of the **dermatitis** in a range from about 5 to about 8, an anti-inflammatory agent, and a wound healing composition. In one embodiment the wound healing composition comprises (a) pyruvate; (b) an **antioxidant**; (c) a mixture of saturated and unsaturated fatty acids. The therapeutic dermatological-wound healing compositions may be utilized in a wide variety of topical pharmaceutical products. This invention also relates to methods for preparing and using the therapeutic dermatological-wound healing compositions and the pharmaceutical products in which the compositions may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 38 OF 46 USPATFULL

ACCESSION NUMBER: 96:120594 USPATFULL
TITLE: Rinse-off water-in-oil-in-water compositions
INVENTOR(S): Herb, Craig A., Chicago, IL, United States
Chen, Liang B., Hoffman Estates, IL, United States
Chung, Judy B., Glenview, IL, United States
Long, Michelle A., Lombard, IL, United States
Sun, Wei M., Palatine, IL, United States
Newell, Gerald P., Hoffman Estates, IL, United States
Kamis, Kimberly, Glenview, IL, United States
Brucks, Richard M., Chicago, IL, United States
PATENT ASSIGNEE(S): Helene Curtis, Inc., Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5589177		19961231
APPLICATION INFO.:	US 1994-349963		19941206 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bleutge, John C.		
ASSISTANT EXAMINER:	Harrison, Robert H.		
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2917		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Rinse-off, water-in-oil-in-water multiple emulsion compositions are disclosed. The multiple emulsion compositions comprise an external aqueous phase optionally incorporating an emulsifier and/or a second topically-active compound. The internal phase comprises a primary water-in-oil emulsion, wherein the primary emulsion comprises a first topically-active compound, a surfactant phase, an oil phase, and water.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 39 OF 46 USPATFULL

ACCESSION NUMBER: 96:113625 USPATFULL
TITLE: Remedy for dermatopathy and metallothionein inducer
INVENTOR(S): Otsu, Yoshiro, Minoo, Japan
Arima, Yaeno, Kobe, Japan

Nakajima, Katsuyuki, Maebashi, Japan
 Adachi, Masakazu, Takasaki, Japan
 Muramatsu, Tsutomu, Nara, Japan
 Hanada, Katsumi, Hirosaki, Japan
 PATENT ASSIGNEE(S): Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
 Japan Immunoresearch Laboratories Co., Ltd., Gunma, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5582817		19961210
	WO 9314748		19930805
APPLICATION INFO.:	US 1993-122585		19931001 (8)
	WO 1993-JP130		19930203
			19931004 PCT 371 date
			19931004 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1992-17612	19920203
	JP 1992-113633	19920506
	JP 1992-325633	19921204
	JP 1992-348618	19921228
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dodson, Shelley A.	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1997	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Zinc salts, zinc complexes or salts thereof of a compound selected from the group consisting of nicotinamides, picolinamides, 3,4-dihydroxybenzoic acids, amino acids, peptides, hinokitiols and pyridine carboxylic acids represented by formula (1): ##STR1## possess a metallothionein inducing effect, effect of suppressing the production of **sunburn** cells, and therefore, useful as cosmetics and as drugs which are for ameliorating **sunburn**, preventing **sunburn**, ameliorating skin diseases, relieving irradiation disorders, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 40 OF 46 USPATFULL

ACCESSION NUMBER: 96:82439 USPATFULL
 TITLE: Processed product for skin and hair treatment
 INVENTOR(S): Dixon, Gary W., P.O. Box 5835, Kingsport, TN, United States 37663-0835

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5554361		19960910
APPLICATION INFO.:	US 1995-377501		19950124 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-184839, filed on 21 Jan 1994, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Clardy, S. Mark		
LEGAL REPRESENTATIVE:	Brown, M. Alex		
NUMBER OF CLAIMS:	16		

EXEMPLARY CLAIM: 1
LINE COUNT: 2330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A processed product for hair and skin treatment, having binary and tertiary fluid phase levels prior to remixing and therapeutic use is disclosed. The invention discloses defined amounts of admixed components including an Iodine complex having tincture of iodine solution and povidone-iodine compound, a diluting fluid complex having a water and mineral oil constituent, and a cod liver oil component, which, after admixing, are ambiently exposed to a photon-light-energy component from sunlight or substantially equivalent artificial light to produce a processed product having at least binary product reaction fluid levels and containing a nucleophilically iodinated cod liver oil compound. The composition is mixed prior to therapeutic application of targeted hair, skin, mucosal or internal areas of a human or animal, mixing the fluid levels to provide synergistic properties and enhanced delivery of the remaining iodine-reaction components and the iodinated cod liver oil compound contained in the product, enhancing the effect and delivery to targeted areas of vitamins A and D and other constituents in the processed reaction product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 41 OF 46 USPATFULL

ACCESSION NUMBER: 96:3758 USPATFULL

TITLE: Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers for physiological active agents

INVENTOR(S): Rajadhyaksha, Vithal J., 27436 Esquina, Mission Viejo, CA, United States 92691

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5482965		19960109
APPLICATION INFO.:	US 1993-115772		19930903 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1991-672020, filed on 19 Mar 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Criares, T. J.		
LEGAL REPRESENTATIVE:	Knobbe, Martens, Olson & Bear		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1187		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and compositions for enhancing absorption of topically administered physiologically active agents through the skin and mucous membranes of humans and animals in a transdermal device or formulation for local or systemic use, comprising a therapeutically effective amount of a pharmaceutically active agent and a non-toxic, effective amount of penetration enhancing agent of the formula I or a physiologically acceptable salt thereof: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 42 OF 46 USPATFULL

ACCESSION NUMBER: 95:97047 USPATFULL

TITLE: Chelator compositions comprising .alpha.-diamine compounds

INVENTOR(S): Bush, Rodney D., Fairfield, OH, United States
Bissett, Donald L., Hamilton, OH, United States

PATENT ASSIGNEE(S): The Procter & Gamble Company, Cincinnati, OH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5462963		19951031
APPLICATION INFO.:	US 1991-739933		19910802 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1990-514892, filed on 26 Apr 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Graff, Milton B., Yetter, Jerry J., Howell, John M.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1994		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention involves photoprotective compositions which are useful for topical application to prevent damage to skin caused by acute or chronic exposure to **ultraviolet** light comprising chelating agents having the structure: ##STR1## wherein each --R.sup.1 is independently selected from the group consisting of alkyl, aryl, heteroaryl and heterocycle, or the --R.sup.1 's are covalently bonded together to form a cyclic alkyl or heterocyclic ring; --R.sup.2 and --R.sup.3 are --OR.sup.4, in which case there is no bond or a polar bond between --R.sup.2 and the nitrogen covalently bonded to --R.sup.3, each --R.sup.4 being independently selected from the group consisting of hydrogen, alkyl and aryl, except that both --R.sup.4 's are not methyl when both --R.sup.1 's are furyl; or --R.sup.2 is --O-- and is covalently bonded to the nitrogen which is covalently bonded to --R.sup.3, and --R.sup.3 is --O-- (there being a + charge on the nitrogen to which it is bonded) or nil;

wherein the .alpha.-diamine compounds consist essentially of compounds wherein .dbd.NR.sup.2 and .dbd.NR.sup.3 are in amphi configuration when both --R.sup.2 and --R.sup.3 are --OH, and when both --R.sup.1 's are furyl or the --R.sup.1 's are covalently bonded together to form a cyclohexanedione structure.

Methods for using such compositions to prevent damage to skin caused by acute or chronic exposure to **ultraviolet** light are also involved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 43 OF 46 USPATFULL
ACCESSION NUMBER: 95:38456 USPATFULL
TITLE: Method and composition for skin depigmentation
INVENTOR(S): Zaias, Nardo, 9-Island Ave. #2101, Miami Beach, FL, United States 33139

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5411741		19950502
APPLICATION INFO.:	US 1993-99491		19930729 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Shlesinger, Arkwright & Garvey		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
LINE COUNT:	464		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition and method for skin depigmentation comprising the steps of encapsulating an effective amount of a water-soluble melanin inhibiting compound with a liposome, suspending the encapsulated melanin inhibiting compound within a topical vehicle, topically applying to the epidermis of the skin the suspended and encapsulated melanin inhibiting compound whereby the liposomes are transdermally delivered to the basal cell region of the epidermis causing interference with the biochemical synthesis of melanin in situ and subsequent depigmentation of the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 44 OF 46 USPATFULL

ACCESSION NUMBER: 90:93000 USPATFULL

TITLE: Method of and composition for the prevention of solar radiation exposure-induced formation of carcinogenic skin lipid degradation products

INVENTOR(S): Voyt, Walter F., 604 E. Palladium Dr., Joliet, IL, United States 60435

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4975272		19901204
APPLICATION INFO.:	US 1987-27416		19870318 (7)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1984-630336, filed on 12 Jul 1984, now abandoned which is a continuation of Ser. No. US 1979-66705, filed on 15 Aug 1979, now abandoned which is a continuation-in-part of Ser. No. US 1978-970060, filed on 15 Dec 1978, now abandoned which is a continuation of Ser. No. US 1976-740646, filed on 10 Nov 1976, now patented, Pat. No. US 4144325		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ore, Dale R.		
LEGAL REPRESENTATIVE:	Neuman, Williams, Anderson & Olsen		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1845		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of and composition for the prevention of solar radiation absorption-induced formation of carcinogenic skin lipid degradation products, particularly malonaldehyde, consisting of the application, prior to exposure of the skin to natural or artificial sources of solar radiation, of a composition comprising an **ultraviolet** screen--effective amount of an **ultraviolet** absorbing compound selected from the group consisting of a salicylate, a para-aminobenzoate, an alkyl ester of para-dialkylaminobenzoic acid, a benzophenone, a cinnamate, a naphthoate, an acid-esterified gallate and mixtures thereof; at least one non-hindered, non-acid esterified, oil soluble, phenolic substituent-bearing latent oxidation inhibitor compound, such as the tocopherols, alcoholic esters of gallic acid, nordihydroguaiaretic acid, and mixtures thereof, the total concentration of said inhibitor present constituting a pro-oxidant-effective amount sufficient to demonstrate pro-oxidant properties, said inhibitor concentration further being insufficient to constitute an **ultraviolet** screen-effective amount demonstrating **ultraviolet** screening properties; and an inert carrier vehicle for said compounds comprising an oil soluble component, the vehicle being non-toxic and non-irritating to the skin. Utilization of an oil soluble **ultraviolet** absorbing compound obviates the necessity for a separate oil soluble component-containing carrier vehicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 45 OF 46 USPATFULL

ACCESSION NUMBER: 82:32722 USPATFULL
TITLE: Sunscreening agent
INVENTOR(S): Holick, Michael F., Sudbury, MA, United States
PATENT ASSIGNEE(S): Massachusetts General Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4338293		19820706
APPLICATION INFO.:	US 1981-238075		19810225 (6)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Roberts, Elbert L.		
LEGAL REPRESENTATIVE:	Oblon, Fisher, Spivak, McClelland & Maier		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1,7		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	353		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A sunscreening composition which comprises a sunscreening amount of a .DELTA..^{5,7} steroidal diene and a topical carrier, with the proviso that the .DELTA..^{5,7} steroidal diene is not a precursor to a biologically active vitamin D compound.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 46 OF 46 USPATFULL

ACCESSION NUMBER: 82:22757 USPATFULL
TITLE: Topical acylaminophenols
INVENTOR(S): Nashed, Wilson, North Brunswick, NJ, United States
Rovee, David T., Bridgewater, NJ, United States
Gander, Robert J., Whitehouse, NJ, United States
PATENT ASSIGNEE(S): Johnson & Johnson Products, Inc., New Brunswick, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4329366		19820511
APPLICATION INFO.:	US 1981-239862		19810302 (6)
RELATED APPLN. INFO.:	Division of Ser. No. US 1979-92296, filed on 8 Nov 1979, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Friedman, Stanley J.		
LEGAL REPRESENTATIVE:	Newman, Irving		
NUMBER OF CLAIMS:	11		
EXEMPLARY CLAIM:	1		
LINE COUNT:	545		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Treatment of inflammation by applying topically a selected acylaminophenol in a pharmaceutically acceptable topical vehicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:42:47 ON 09 JAN 2002)

FILE 'REGISTRY' ENTERED AT 09:43:20 ON 09 JAN 2002
E CHOLECALCIFEROL/CN

L1 1 S E3

FILE 'MEDLINE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 09:44:48 ON 09 JAN 2002

L2 7452 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT?
L3 372928 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT? OR ULTRAVIOLET
L4 19 S L2 AND L1
~ L5 18 DUP REM L4 (1 DUPLICATE REMOVED)
- L6 5 S (SUN(W)BURN OR SUNBURN) AND RADIATION(W)DERMATIT?
L7 4 DUP REM L6 (1 DUPLICATE REMOVED)
L8 720 S SUNBURN AND DERMATITIS
L9 228 S L8 AND ULTRAVIOLET
L10 219 DUP REM L9 (9 DUPLICATES REMOVED)
L11 46 S L10 AND ANTIOXIDANT

L44 ANSWER 1 OF 8 USPATFULL

ACCESSION NUMBER: 2001:107939 USPATFULL

TITLE: Internal liquid composition contained as internal liquid in a releasing container and releasing container product

INVENTOR(S): Iijima, Kazuo, Osaka, Japan
Uenoyama, Haruhisa, Osaka, Japan
Sakai, Takuya, Osaka, Japan

PATENT ASSIGNEE(S): Kyowa Industrial Co., Ltd., Osaka, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6258857	B1	20010710
APPLICATION INFO.:	US 1999-244088		19990204 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Lovering, Richard D.		
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP		
NUMBER OF CLAIMS:	6		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1409		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to an internal liquid composition contained in a releasing container such as an aerosol container, and a releasing container product containing such composition. The following three types are proposed as the composition. The first type is a blending of inorganic porous fine particles carrying a chemical, disperse solution, acrylic acid polymer, and alkali. The second type is a blending of inorganic porous fine particles carrying a chemical, disperse solution, and synthetic resin fine particles. The third type is a blending of inorganic porous fine particles carrying a chemical, disperse solution, acrylic acid polymer, alkali, and synthetic resin fine particles. As inorganic porous fine particles, for example, silicic anhydride porous fine particles may be used. The chemical to be carried by the inorganic porous fine particles includes perfume, insect repellent, agricultural chemical, deodorant, plant extract, ultraviolet blocker, antioxidant, antipruritic, hair growth promoter, vitamin, antiperspirant, **sunburn** remedy, antiseptic, moisturizer, styptic, oil, and others. As disperse solution, water, alcohol, ether and other organic solvents may be used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 2 OF 8 USPATFULL

ACCESSION NUMBER: 2001:97901 USPATFULL

TITLE: Inhibition of UV-induced immune suppression and interleukin-10 production by cytoprotective tamarind oligosaccharides

INVENTOR(S): Strickland, Faith, Galveston, TX, United States
Pelley, Ronald, Galveston, TX, United States
Albersheim, Peter, Athens, GA, United States
Darvill, Alan, Athens, GA, United States
Pauly, Markus, Frederiksberg, Denmark
Eberhard, Stefan, Athens, GA, United States(4)PATENT ASSIGNEE(S): Board of Regents, The University of Texas System,
Austin, TX, United States (U.S. corporation)
University of Georgia Research Foundation Inc., Athens,
GA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 6251878	B1	20010626
APPLICATION INFO.:	US 1999-348977		19990707 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-92444	19980710 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Jarvis, William R. A.	
ASSISTANT EXAMINER:	Kim, Vickie	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski L.L.P.	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	2332	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions are disclosed for the prevention and/or treatment of immunological damage to skin exposed to ultraviolet irradiation. The compositions described herein include biologically active tamarind seed xyloglucan oligosaccharides obtained via treatment of tamarind xyloglucan with a fungal .beta.-glucanase. Advantageously, the cytoprotective tamarind seed xyloglucan oligosaccharides are stable at ambient conditions. In one aspect, the composition includes an aqueous solution of tamarind seed xyloglucan oligosaccharides having a concentration of at least 10.sup.-6 .mu.g per mL of the solution. In another aspect, the method includes preventing the suppression of delayed type hypersensitivity. In yet another aspect, the invention includes reducing the amount of interleukin-10 produced by keratinocytes in the skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 3 OF 8 USPATFULL

ACCESSION NUMBER:	1999:155356 USPATFULL
TITLE:	Hydrophilic and hydrophobic polyether polyurethanes and uses therefor
INVENTOR(S):	Reich, Murray H., Princeton, NJ, United States Teffenhardt, John, Edison, NJ, United States Kuzma, Jirina, Princeton, NJ, United States
PATENT ASSIGNEE(S):	Tyndale Plains-Hunter, Ltd., Lawrenceville, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5993972		19991130
APPLICATION INFO.:	US 1998-40692		19980318 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-915583, filed on 26 Aug 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24526	19960826 (60)
	US 1997-40094	19970307 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Gorr, Rachel	
LEGAL REPRESENTATIVE:	Mathews, Collins, Shepherd & Gould, P.A.	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4868	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved amphiphilic diol is prepared with a controlled type and amount of alkylene glycol, catalyst, hydrophobic and hydrophilic diol with diisocyanate and water. Critical selection of the type, molecular weight and ratios of hydrophilic to hydrophobic diol, isocyanate to hydroxyl groups, average molecular weight of the diol component, the amount of water in the reaction mixture produces a polyurethane having high slip, Shore A Hardness values, wet tensile strength and tear strength. This invention also includes uses of the polyurethane in catheters, shaving products, synthetic valves, veins and arteries, stents, ports, shunts and coatings. Preferably, the polyurethane is used in combination with a filler for application to rubber gloves. In addition, dispersions, lotions, gels and solutions can be formed of the polyurethane.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 4 OF 8 USPATFULL

ACCESSION NUMBER: 1999:121521 USPATFULL
TITLE: Hydrophobic and hydrophilic polyether polyurethanes and uses therefor
INVENTOR(S): Reich, Murray H., Princeton, NJ, United States
Nelson, Ken, Lambertville, NJ, United States
Kuzma, Jirina, Princeton, NJ, United States
PATENT ASSIGNEE(S): Tyndale Plains-Hunter, Ltd., Lawrenceville, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5962620		19991005
APPLICATION INFO.:	US 1997-915583		19970826 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-24526	19960826 (60)
	US 1997-40094	19970307 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Gorr, Rachel
LEGAL REPRESENTATIVE: Mathews, Collins, Shepherd & Gould, P.A.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 4241

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An improved amphiphilic diol is prepared with a controlled type and amount of alkylene glycol, hydrophobic and hydrophilic diol with diisocyanate and water. Critical selection of the type, molecular weight and ratios of hydrophilic to hydrophobic diol, isocyanate to hydroxyl groups, average molecular weight of the diol component, the amount of water in the reaction mixture produces a polyurethane having high slip, Shore A Hardness values, wet tensile strength and tear strength. This invention also includes uses of the polyurethane in catheters, shaving products, synthetic valves, veins and arteries, stents, ports, shunts and coatings. Preferably, the polyurethane is used in combination with a filler for application to rubber gloves. In addition, dispersions, lotions, gels and solutions can be formed of the polyurethane.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 5 OF 8 USPATFULL

ACCESSION NUMBER: 97:59209 USPATFULL
TITLE: Kappa agonist compounds and pharmaceutical formulations thereof

INVENTOR(S): Kruse, Lawrence I., Haddonfield, NJ, United States
 Kumar, Virendra, Paoli, PA, United States
 Chang, An-Chih, Phoenixville, PA, United States
 DeHaven-Hudkins, Diane L., Chester Springs, PA, United States
 Farrar, John J., Chester Springs, PA, United States
 Maycock, Alan L., Malvern, PA, United States
 PATENT ASSIGNEE(S): Adolor Corporation, Malvern, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5646151		19970708
APPLICATION INFO.:	US 1996-612680		19960308 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	McKane, Joseph		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1630		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds, compositions and method of treating hyperalgesia comprising a compound of formula I, II, III and IV as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 6 OF 8 USPATFULL
 ACCESSION NUMBER: 93:74403 USPATFULL
 TITLE: Water-dispersible copolymer containing UVA and UVB light-absorbing monomers
 INVENTOR(S): Langer, Matthew E., New City, NY, United States
 Khorshahi, Ferial, Leonia, NJ, United States
 Lee, Katherine, Auburn, MA, United States
 PATENT ASSIGNEE(S): Lever Brothers Company, Division of Conopco, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5243021		19930907
APPLICATION INFO.:	US 1992-872874		19920423 (7)
DISCLAIMER DATE:	20090728		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-731565, filed on 17 Jul 1991, now patented, Pat. No. US 5134223		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Acquah, Samuel A.		
LEGAL REPRESENTATIVE:	Koatz, Ronald A.		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1519		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention is concerned with novel water-dispersible or water-soluble copolymers which contain at least one UVA light-absorbing monomer, one UVB light-absorbing monomer, one hydrophilic monomer, and optionally one hydrophobic monomer component. The UVA light-absorbing monomer absorbs at .lambda.max ultraviolet light in the 320-400 nm range. The UVB light-absorbing monomer absorbs at .lambda.max ultraviolet light in the 290-320 nm range.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 7 OF 8 USPATFULL

ACCESSION NUMBER: 83:38377 USPATFULL
TITLE: Wound-healing compositions containing povidone-iodine
INVENTOR(S): Knutson, Richard A., 130 N. Shelby St., Greenville, MS,
United States 38701

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4401651		19830830
APPLICATION INFO.:	US 1980-171261		19800722 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1979-31162, filed on 18 Apr 1979, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schenkman, Leonard		
LEGAL REPRESENTATIVE:	Berman, Aisenberg & Platt		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1363		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Admixtures of (a) an antifungal/antibacterial agent, such as povidone-iodine, (b) sugar and (c) suitable carrier are substantially non-allergenic, have excellent healing properties when applied to burns or open wounds and serve as an effective barrier to the growth of healing tissue into gauze or similar dressing.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L44 ANSWER 8 OF 8 USPATFULL

ACCESSION NUMBER: 72:14977 USPATFULL
TITLE: TREATMENT OF MONOMERIC AND POLYMERIC SYSTEMS WITH HIGH INTENSITY PREDOMINANTLY CONTINUUM LIGHT RADIATION
INVENTOR(S): Osborn, Claiborn Lee, So. Charleston, WV, United States
Trecker, David John, So. Charleston, WV, United States
PATENT ASSIGNEE(S): Union Carbide Corporation, New York, NY, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3650669		19720321
APPLICATION INFO.:	US 1970-69041		19700902 (5)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1969-794752, filed on 28 Jan 1969, now abandoned And a continuation-in-part of Ser. No. US 1969-838460, filed on 2 Jul 1969, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Tillman, Murray		
ASSISTANT EXAMINER:	Turer, Richard B.		
LEGAL REPRESENTATIVE:	Rose; Paul A., Cozzi; Aldo John, Fazio; Francis M.		
NUMBER OF CLAIMS:	33		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	2337		

AB High intensity predominantly continuum light radiation having an intensity of at least about 350 watts per square centimeter steradian is used to polymerize monomers and to crosslink polymers. A convenient source of this high intensity predominantly continuum light radiation is a swirl-flow plasma arc radiation source. The polymers can be crosslinked in the form of films, fibers, molded or extruded shaped articles, coatings, laminated articles, and the like. The process produces finished articles having known commercial utility.

=> d his

(FILE 'HOME' ENTERED AT 09:42:47 ON 09 JAN 2002)

FILE 'REGISTRY' ENTERED AT 09:43:20 ON 09 JAN 2002

E CHOLECALCIFEROL/CN

L1 1 S E3

FILE 'MEDLINE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 09:44:48 ON 09 JAN 2002

L2 7452 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT?
L3 372928 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT? OR ULTRAVIOLET
L4 19 S L2 AND L1
L5 18 DUP REM L4 (1 DUPLICATE REMOVED)
L6 5 S (SUN(W)BURN OR SUNBURN) AND RADIATION(W)DERMATIT?
L7 4 DUP REM L6 (1 DUPLICATE REMOVED)
L8 720 S SUNBURN AND DERMATITIS
L9 228 S L8 AND ULTRAVIOLET
L10 219 DUP REM L9 (9 DUPLICATES REMOVED)
L11 46 S L10 AND ANTIOXIDANT
L12 3 S L4 AND "VITAMIN A" AND "VITAMIN E"
L13 2 DUP REM L12 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 10:08:53 ON 09 JAN 2002

E .ALPHA.-LIPOLIC/CN

E .ALPHA.-LIPOLIC ACID/CN

E .ALPHA.-LIPOLIC-/CN

E .ALPHA.-LIPOIC ACID/CN

L14 1 S E3

FILE 'MEDLINE, BIOSIS, USPATFULL, CAPLUS' ENTERED AT 10:11:23 ON 09 JAN 2002

L15 0 S L14 AND L13
L16 0 S L14 AND L5
L17 18 S L2 AND L5
L18 4 S L2 AND L14
L19 4 DUP REM L18 (0 DUPLICATES REMOVED)
L20 0 S L4 AND QUERCETIN
L21 30 S L2 AND QUERCETIN
L22 30 DUP REM L21 (0 DUPLICATES REMOVED)
L23 0 S L22 AND L1
L24 7 S L22 AND ("VITAMIN A" OR "VITAMIN E")
L25 3 S L24 AND ASCORBYL(W)PALMITATE
L26 3 DUP REM L25 (0 DUPLICATES REMOVED)
L27 0 S L1 AND "VITAMIN A" AND "VITAMIN E" AND ASCORBYL(W)PALMITATE A
L28 0 S L1 AND ("VITAMIN A" OR "VITAMIN E") AND ASCORBYL(W)PALMITATE
L29 0 S L1 AND ASCORBYL(W)PALMITATE AND QUERCETIN AND L14
L30 0 S ("VITAMIN A" OR "VITAMIN E") AND ASCORBYL(W)PALMITATE AND QU
L31 0 S (L1 OR ("VITAMIN A" OR "VITAMIN E")) AND ASCORBYL(W)PALMITAT
L32 1 S L4 AND (HYDROPHILIC(W)OINTMENT OR HYDROPHILIC(W)PETROLATUM O
L33 0 S L4 AND ?PANTHENOL
L34 126 S L2 AND ?PANTHENOL
L35 126 DUP REM L34 (0 DUPLICATES REMOVED)
L36 1 S L35 AND (HYDROPHILIC(W)OINTMENT OR ABSORPTION(W)BASE OR HYDR
L37 0 S L4 AND HYDROXYMETHYL(W)CELLULOSE
L38 28 S L2 AND HYDROXYMETHYL(W)CELLULOSE
L39 28 DUP REM L38 (0 DUPLICATES REMOVED)
L40 0 S L4 AND (CARBOWAX OR METHOXY(W)POLYETHYLENE(W)GLYCOL OR ACRYL
L41 69 S L2 AND (CARBOWAX OR METHOXY(W)POLYETHYLENE(W)GLYCOL OR ACRYLI
L42 67 DUP REM L41 (2 DUPLICATES REMOVED)
L43 8 S L2 AND (CARBOWAX OR METHOXY(W)POLYETHYLENE(W)GLYCOL OR ACRYLI
L44 8 DUP REM L43 (0 DUPLICATES REMOVED)

L39 ANSWER 1 OF 28 USPATFULL

ACCESSION NUMBER: 2001:226644 USPATFULL
TITLE: Amine compounds, their production and use
INVENTOR(S): Suzuki, Nobuhiro, Tsukuba, Japan
Kato, Kaneyoshi, Kawanishi, Japan
Takekawa, Shiro, Tsukuba, Japan
Terauchi, Jun, Ikeda, Japan
Endo, Satoshi, Takatsuki, Japan
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Osaka, Japan
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6329389	B1	20011211
	WO 9952875		19991021
APPLICATION INFO.:	US 1999-424285		19991119 (9)
	WO 1999-JP1871		19990408
			19991119 PCT 371 date
			19991119 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-96422	19980408
	JP 1998-345328	19981204
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Seaman, D. Margaret	
LEGAL REPRESENTATIVE:	Philippe Y. Riesen, Chao, Mark	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	6360	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a compound of the formula: ##STR1##

wherein Ar represents an aromatic group which may be substituted;

X represents methylene, S, SO, SO.sub.2 or CO;

Y represents a spacer having a main chain of 2 to 5 atoms;

n represents an integer of 1 to 5;

i) R.sup.1 and R.sup.2 each represents a hydrogen atom or a lower alkyl which may be substituted,

ii) R.sup.1 and R.sup.2 form, taken together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic ring which may be substituted, or

iii) R.sup.1 or R.sup.2 together with --(CH.sub.2).sub.n--N.dbd. form, bonded to a component atom of Ring B, a spiro-ring which may be substituted;

Ring A represents an aromatic ring which may be substituted;

Ring B represents a 4- to 7-membered nitrogen-containing non-aromatic ring which may be further substituted by alkyl or acyl,

with a proviso that X represents S, SO, SO.sub.2 or CO when Ring A has as a substituent a group represented by the formula:

--NHCOR.sup.11

where R.sup.11 represents alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group represented by the formula:

--NHR.sup.12

where R.sup.12 represents alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, or a salt thereof; which has an excellent somatostatin receptor binding inhibition action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 2 OF 28 USPATFULL

ACCESSION NUMBER: 2000:131425 USPATFULL
TITLE: Emollient esters based upon capryl alcohol and isostearic acid
INVENTOR(S): Fogel, Arnold W., Upper Saddle River, NJ, United States
PATENT ASSIGNEE(S): Bernel Chemical Company, Inc., Englewood, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6126951		20001003
APPLICATION INFO.:	US 1998-115029		19980714 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dodson, Shelley A.		
ASSISTANT EXAMINER:	Lamm, Marina		
LEGAL REPRESENTATIVE:	Coleman, Henry D., Sudol, R. Neil		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	759		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel emollient compound capryl isostearate, which is obtained from capryl alcohol and isostearic acid. These emollient compounds may then be used in dermatological products for their unexpected characteristics and as silicone-free carbon based replacements for the volatile cyclomethicones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 3 OF 28 USPATFULL

ACCESSION NUMBER: 2000:105460 USPATFULL
TITLE: Systems and methods for topical treatment with nitric oxide
INVENTOR(S): Seitz, William A., Dickinson, TX, United States
Garfield, Robert E., Friendswood, TX, United States
Balaban, Alexandru T., Columbia, MD, United States
Stewart, Randall J., Galveston, TX, United States
PATENT ASSIGNEE(S): Nitric Oxide Solutions, Dickinson, TX, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6103275		20000815
APPLICATION INFO.:	US 1998-95174		19980610 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Reamer, James H.		
LEGAL REPRESENTATIVE:	Hodgins, Daniel S.		

NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1,12
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 847

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A simple, biocompatible system and procedure for generating nitric oxide (NO) is described. A mixture of powdered sodium nitrite, ascorbic acid, and maleic acid (or another organic acid of adequate strength) immediately generates nitric oxide (NO) on treatment with water. To slow down the NO generation, one may prepare an ointment from a nonaqueous medium (petrolatum, vaseline) and the three powdered ingredients, which on being applied topically on the skin will release NO as water permeates through this medium; alternatively, one may convert the aqueous sodium nitrite solution into a gel with hydroxyethylcellulose (or other gel-forming compound) and combine this gel with another gel obtained from aqueous ascorbic and maleic acids with hydroxyethylcellulose for topical application (on intact skin, burns, intra-cavity, etc.). The two gels may be admixed immediately before use (possibly from a single container with separate chambers and dual nozzle, via pushing or squeezing the two gels through the nozzle), or may be applied in sandwich-like fashion (possibly as a transdermal patch) for further slowing down the delivery of NO.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 4 OF 28 USPATFULL

ACCESSION NUMBER: 1999:163237 USPATFULL
TITLE: Medicated applicator sheet for topical drug delivery
INVENTOR(S): Smith, James A., Chatham, MA, United States
Klein, Robert W., Fort Washington, PA, United States
PATENT ASSIGNEE(S): Creative Products Resource, Inc., Fairfield, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 6001380		19991214
APPLICATION INFO.:	US 1997-938335		19970925 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-683505, filed on 17 Jul 1996, now abandoned which is a continuation of Ser. No. US 1994-226698, filed on 12 Apr 1994, now patented, Pat. No. US 5538732		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Dees, Jose G.		
ASSISTANT EXAMINER:	Shelborne, Kathryne E.		
LEGAL REPRESENTATIVE:	Nash & Titus, LLC		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	874		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for applying a plurality, preferably two, of dermatological agents to the skin from a single dispensing and applicator sheet comprising a plurality of discrete areas comprising at least two dermatological agents which are simultaneously released from the sheet and applied to the afflicted skin area when the sheet is rubbed over wet skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 5 OF 28 USPATFULL

ACCESSION NUMBER: 1998:134379 USPATFULL

TITLE: Electromagnetically triggered, responsive gel based drug delivery device

INVENTOR(S): Leeb, Steven B., Belmont, MA, United States
Lupton, Elmer C., Boston, MA, United States
Yu, Xiaohong, Boston, MA, United States
Hovorka, George, Boston, MA, United States

PATENT ASSIGNEE(S): MedLogic Global Corporation, Colorado Springs, CO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5830207		19981103
APPLICATION INFO.:	US 1997-791368		19970130 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-393971, filed on 24 Feb 1995, now patented, Pat. No. US 5643246, issued on 7 Jul 1997		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lacyk, John P.		
ASSISTANT EXAMINER:	Gilbert, Samuel		
LEGAL REPRESENTATIVE:	Burns, Doane, Swecker & Mathis, L.L.P.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	683		

AB A system for remotely inducing a phase transition in a gel is provided. The system includes a gel capable of volume change in response to an environmental stimulus, a seed material in contact with the gel, and generating a time-varying magnetic or a time-varying electric or electromagnetic field in the proximity of the gel to produce the environmental stimulus. In a preferred embodiment, the environmental stimulus is temperature.

L39 ANSWER 6 OF 28 USPATFULL

ACCESSION NUMBER: 1998:87587 USPATFULL

TITLE: Genital lubricant with zinc salt, labelled as anti-viral agent

INVENTOR(S): Kelly, Patrick D., 33 Berry Oaks, St. Louis, MO, United States 63122

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5785054		19980728
APPLICATION INFO.:	US 1995-464273		19950605 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-57001, filed on 3 May 1993, now patented, Pat. No. US 5499377, issued on 12 Mar 1996 And Ser. No. US 1994-361967, filed on 22 Dec 1994, now patented, Pat. No. US 5589551 which is a continuation-in-part of Ser. No. US 1993-56480, filed on 3 May 1993, now abandoned, said Ser. No. US -57001 And Ser. No. US -56480, each Ser. No. US - which is a continuation-in-part of Ser. No. US 1991-737169, filed on 29 Jul 1991, now patented, Pat. No. US 5208031, issued on 4 May 1993 which is a continuation-in-part of Ser. No. US 1990-528495, filed on 25 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-362058, filed on 6 Jun 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Brown, Michael A.		

LEGAL REPRESENTATIVE: Kelly, Patrick D.
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 3 Drawing Page(s)
LINE COUNT: 1407

AB This invention relates to an article of manufacture including a genital lubricant containing a selected non-irritating, water-soluble zinc salt at an anti-viral concentration, within a package that is provided with a label indicating that the lubricant is effective as an anti-viral agent against at least one type of sexually transmitted virus (such as genital herpes viruses, human immunodeficiency viruses, hepatitis viruses, or papilloma viruses). One such lubricant includes a lubricant gel in a plastic-walled tubular package, for use with or without a condom; another such lubricant includes a condom lubricant, coated on a condom and sealed along with the condom inside a disposable plastic pouch. The zinc salt must be water-soluble and have substantial dissociation rates to release divalent zinc ions, and the lubricant must not cause genital irritation or other adverse effects, even if used repeatedly over a period of months or years. The zinc-containing lubricants described herein can reduce the risk that a previously uninfected person will become infected by sexually transmitted viruses, and the labelling information will help promote efficacy and slow the spread of incurable viruses.

L39 ANSWER 7 OF 28 USPATFULL

ACCESSION NUMBER: 97:65890 USPATFULL
TITLE: Method and compositions for the production of chlorine dioxide
INVENTOR(S): Roozdar, Habib, Nesconset, NY, United States
PATENT ASSIGNEE(S): ARCO Research Co., Inc., Melville, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5651996		19970729
APPLICATION INFO.:	US 1994-358766		19941219 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-231283, filed on 22 Apr 1994, now patented, Pat. No. US 5407656 which is a continuation-in-part of Ser. No. US 1993-93529, filed on 19 Jul 1993, now patented, Pat. No. US 5380518 which is a continuation-in-part of Ser. No. US 1992-846468, filed on 4 Mar 1992, now abandoned And Ser. No. US 1992-980262, filed on 23 Nov 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Pak, John		
LEGAL REPRESENTATIVE:	McAulay Fisher Nissen Goldberg & Kiel, LLP		
NUMBER OF CLAIMS:	3		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1589		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method for producing chlorine dioxide (ClO.sub.2) disinfecting solution which preferably minimizes the amount of residual chlorite ion (ClO.sub.2 --) so that the disinfecting solution can be used in a number of industries, preferably including the food, food processing, drinking water, pharmaceutical production, medical and dental industries. Chlorine dioxide generating solutions which are substantially corrosion free as well as gel formulations are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 8 OF 28 USPATFULL

ACCESSION NUMBER: 97:63767 USPATFULL
TITLE: Pharmaceutical compositions and methods
INVENTOR(S): Bockow, Barry I., 16122 8th Ave. SW., Seattle, WA,
United States 98166

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650157		19970722
APPLICATION INFO.:	US 1994-247682		19940322 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-53508, filed on 26 Apr 1993, now abandoned which is a continuation of Ser. No. US 1991-816833, filed on 30 Dec 1991, now abandoned which is a continuation of Ser. No. US 1990-545414, filed on 27 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1990-520026, filed on 7 May 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Phelan, D. Gabrielle		
LEGAL REPRESENTATIVE:	Seed and Berry LLP		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1069		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Some otherwise desirable oil compositions derived from natural sources are characterized by an unpleasant odor. Fractions or combinations of such oils may also be so characterized. Stable, deodorized oils may be prepared by adding an amount of a deodorizing agent effective to substantially reduce the odor of the derived oil composition, fraction or combination thereof to that oil composition, fraction or combination. The pharmaceutical topical compositions of the present invention contain these stable, deodorized oil compositions and exhibit enhanced penetration properties and achieve enhanced patient response. The improved pharmaceutical compositions of the present invention may be used to manage pain and/or to treat the underlying ailments. Methods of making such topical pharmaceutical compositions are also discussed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 9 OF 28 USPATFULL

ACCESSION NUMBER: 97:56017 USPATFULL
TITLE: Electromagnetically triggered, responsive gel based drug delivery device
INVENTOR(S): Leeb, Steven B., Belmont, MA, United States
Lupton, E. C., Boston, MA, United States
Yu, Xiaohong, Boston, MA, United States
Hovorka, George, Boston, MA, United States
PATENT ASSIGNEE(S): Gel Sciences, Inc., Bedford, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5643246		19970701
APPLICATION INFO.:	US 1995-393971		19950224 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cohen, Lee S.		
ASSISTANT EXAMINER:	Gilbert, Samuel		
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart		

NUMBER OF CLAIMS: 4
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 670

AB A system for remotely inducing a phase transition in a gel is provided. The system includes a gel capable of volume change in response to an environmental stimulus, a seed material in contact with the gel, and generating a time-varying magnetic or a time-varying electric or electromagnetic field in the proximity of the gel to produce the environmental stimulus. In a preferred embodiment, the environmental stimulus is temperature.

L39 ANSWER 10 OF 28 USPATFULL

ACCESSION NUMBER: 97:9787 USPATFULL
TITLE: Genital lubricants containing zinc as an anti-viral agent
INVENTOR(S): Kelly, Patrick D., 33 Berry Oaks, St. Louis, MO, United States 63122

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5599551		19970204
APPLICATION INFO.:	US 1994-361967		19941222 (8)
DISCLAIMER DATE:	20100504		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-56480, filed on 3 May 1993, now abandoned which is a continuation-in-part of Ser. No. US 1991-737169, filed on 29 Jul 1991, now patented, Pat. No. US 5208031, issued on 4 May 1993 which is a continuation-in-part of Ser. No. US 1990-528495, filed on 25 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-362058, filed on 6 Jun 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azruru, Carlos		
LEGAL REPRESENTATIVE:	Kelly, Patrick D.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1263		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to an article of manufacture comprising an aqueous gel containing a selected zinc salt contained within a deformable plastic-walled tubular container, for convenient and consistent use as a topical genital lubricant during acts of sexual intercourse. The zinc salt must be organic, water-soluble, and have substantial dissociation rates to release divalent zinc ions. Suitable zinc salts include zinc acetate, zinc propionate, zinc butyrate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, and zinc lactate. The gel must also contain a thickening agent (such as chemically treated cellulose) and a lubricating agent (such as glycerin), and it must be free of heparin, dextran sulfate, or any other anti-coagulant or other component which poses a substantial risk of adverse effects if the lubricant is used frequently and repeatedly over a period of months or years. The zinc-containing lubricants described herein can reduce the risk that a previously uninfected person will become infected by genital herpes viruses, and possibly by HIV, hepatitis, or papilloma viruses or other sexually transmitted pathogens, during or after intercourse with an infected partner.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:720063 CAPLUS

DOCUMENT NUMBER: 127:351060

TITLE: Topical compositions based on thermal muds and gelling agents

INVENTOR(S): Reiner, Alberto; Reiner, Giorgio

PATENT ASSIGNEE(S): APR Applied Pharma Research S.A., Switz.

SOURCE: Eur. Pat. Appl., 11 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 803246	A1	19971029	EP 1997-201153	19970419
R: DE, ES, FR, GB, IT				
CH 690295	A	20000714	CH 1996-1036	19960424

PRIORITY APPLN. INFO.: CH 1996-1036 A 19960424

AB Gelled compns. based on thermal muds for cosmetic and therapeutic use are described. The process for the prepn. thereof is also described. A mud gel for cellulite contained gelled mud (dry residue) 97.2, escin 0.4, mucopolysaccharide 0.3, deacetylated soya phospholipid 0.5, and preservatives 1.6 g.

L39 ANSWER 12 OF 28 USPATFULL

ACCESSION NUMBER: 96:113626 USPATFULL

TITLE: Ultraviolet screening powder and cosmetics

INVENTOR(S): Nakanishi, Noriyuki, Kawasaki, Japan

Mori, Hiroo, Ichihara, Japan

PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Tokyo, Japan (non-U.S. corporation)

Asahi Glass Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5582818		19961210
APPLICATION INFO.:	US 1995-379953		19950127 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-7546	19940127
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dodson, Shelley A.	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	705	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Herein disclosed are cosmetics having spherical silica containing an ultraviolet reflecting material surface-treated with platy N-lauroyl-L-lysine incorporated therein. According to the present invention, those cosmetics having spherical silica containing a conventional ultraviolet reflecting material blended therewith are improved in cosmetic functions such as spreadability upon application, lubricity upon application, smooth feeling on skins, adhesiveness to skins, water repellency, feeling, etc., maintaining the original ultraviolet screening effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 13 OF 28 USPATFULL

ACCESSION NUMBER: 96:91564 USPATFULL
TITLE: Separately packaged applicator pads for topical
delivery of incompatible drugs
INVENTOR(S): Smith, James A., Chatham, MA, United States
Murphy, Betty J., Upper Montclair, NJ, United States
PATENT ASSIGNEE(S): Creative Products Resource, Inc., North Caldwell, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5562642		19961008
APPLICATION INFO.:	US 1995-434950		19950504 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1993-105877, filed on 11 Aug 1993, now patented, Pat. No. US 5417674, issued on 23 May 1995 which is a division of Ser. No. US 1992-986598, filed on 7 Dec 1992, now patented, Pat. No. US 5254109, issued on 19 Oct 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prebilic, Paul B.		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	2		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1468		

AB The present invention provides a system for applying a plurality,
preferably two, dermatological agents to the skin from a single
dispensing and applicator system comprising a plurality of
compartmentalized applicator pads which may be exposed and sequentially
applied to the afflicted skin area.

L39 ANSWER 14 OF 28 USPATFULL

ACCESSION NUMBER: 96:72921 USPATFULL
TITLE: Method for reducing risk of infection by sexually
transmitted viruses
INVENTOR(S): Kelly, Patrick D., 33 Berry Oaks, St. Louis, MO, United
States 63122

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5545673		19960813
APPLICATION INFO.:	US 1995-368041		19950103 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-57110, filed on 3 May 1993, now abandoned which is a division of Ser. No. US 1991-737169, filed on 29 Jul 1991, now patented, Pat. No. US 5208031, issued on 14 May 1993 , said Ser. No. US -57110 which is a continuation-in-part of Ser. No. US -737169 which is a continuation-in-part of Ser. No. US 1990-528495, filed on 25 May 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-362058, filed on 6 Jun 1989, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Kelly, Patrick D.		
NUMBER OF CLAIMS:	7		

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1264

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is disclosed for reducing the risk of infection by sexually transmitted viruses. This method involves spreading a lubricant fluid containing a selected zinc salt across the surfaces of the penis or vagina, before intercourse, in a manner that causes the lubricant to coat and remain in contact with the genital surfaces throughout intercourse. The zinc salt should be organic, water-soluble, non-irritating, physiologically acceptable, and have a high rate of dissociation, which allows it to release substantial quantities of divalent zinc ions. Suitable zinc salts include zinc acetate, zinc propionate, zinc butyrate, zinc formate, zinc gluconate, zinc glycerate, zinc glycolate, and zinc lactate. A preferred carrier fluid comprises a lubricant gel, which also contains water, a thickening agent (such as chemically treated cellulose) and a lubricating agent (such as glycerin). The lubricant formulation must be free of heparin, dextran sulfate, or any other component that poses a substantial risk of adverse effects if the lubricant is used frequently and repeatedly over a period of months or years. The lubricants disclosed herein preferably should be used with condoms, to enhance the risk-reducing effectiveness of condoms and provide maximum protection; however, these lubricants can also be used without condoms, if desired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 15 OF 28 USPATFULL

ACCESSION NUMBER: 96:65331 USPATFULL
TITLE: Medicated applicator sheet for topical drug delivery
INVENTOR(S): Smith, James A., Chatham, MA, United States
Kline, Robert W., Fort Washington, PA, United States
PATENT ASSIGNEE(S): Creative Products Resource, Inc., North Caldwell, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5538732		19960723
APPLICATION INFO.:	US 1994-226698		19940412 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Howard, S.		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg & Woessner		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	917		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a method for applying a plurality, preferably two, of dermatological agents to the skin from a single dispensing and applicator sheet comprising a plurality of discrete areas comprising at least two dermatological agents which are simultaneously released from the sheet and applied to the afflicted skin area when the sheet is rubbed over wet skin.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 16 OF 28 USPATFULL

ACCESSION NUMBER: 96:45771 USPATFULL
TITLE: Cosmetic or dermatological preparation comprising
delta-aminolevulinic acid content as an active

ingredient
 INVENTOR(S): Uhlmann, Beate, Hamburg, Germany, Federal Republic of
 Mann, Tobias, Hamburg, Germany, Federal Republic of
 Gers-Barlag, Heinrich, Kummerfeld, Germany, Federal
 Republic of
 Sauermann, Gerhard, Wiemersdorf, Germany, Federal
 Republic of
 PATENT ASSIGNEE(S): Beiersdorf Aktiengesellschaft, Hamburg, Germany,
 Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5520905		19960528
APPLICATION INFO.:	US 1994-260843		19940616 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1993-4320871	19930624
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ivy, C. Warren	
ASSISTANT EXAMINER:	Huang, Evelyn	
LEGAL REPRESENTATIVE:	Sprung Horn Kramer & Woods	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	583	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A cosmetic or dermatological preparation comprising .delta.-
 aminolevulinic acid as an active ingredient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 17 OF 28 USPATFULL

ACCESSION NUMBER: 95:105319 USPATFULL
 TITLE: Packaging system with in-tandem applicator pads for
 topical drug delivery
 INVENTOR(S): Smith, James A., Chatham, MA, United States
 Murphy, Betty J., Upper Montclair, NJ, United States
 PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North
 Caldwell, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5470323		19951128
APPLICATION INFO.:	US 1993-105037		19930811 (8)
DISCLAIMER DATE:	20120523		
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-986597, filed on 7 Dec 1992, now patented, Pat. No. US 5242433		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prebilic, Paul		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg & Woessner		
NUMBER OF CLAIMS:	37		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1321		

AB The present invention provides a system for applying a plurality,
 preferably two, dermatological agents to the skin from a single
 dispensing and applicator system comprising a plurality of
 compartmentalized applicator pads which may be exposed and sequentially
 or simultaneously applied to the skin area to be treated. Each of the
 applicator pads in the system are provided with a different

dermatological agent.

L39 ANSWER 18 OF 28 USPATFULL

ACCESSION NUMBER: 95:94490 USPATFULL
TITLE: Method of applying in-tandem applicator pads for
transdermal delivery of a therapeutic agent
INVENTOR(S): Smith, James A., Chatham, MA, United States
Murphy, Betty J., Upper Montclair, NJ, United States
PATENT ASSIGNEE(S): Creative Products Resource, Inc., North Caldwell, NJ,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5460620		19951024
APPLICATION INFO.:	US 1993-117444		19930907 (8)
DISCLAIMER DATE:	20100907		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-986597, filed on 7 Dec 1992, now patented, Pat. No. US 5242433 And a continuation-in-part of Ser. No. US 1992-922887, filed on 31 Jul 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kruter, Jerome L.		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg & Woessner		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1536		

AB The invention provides a method for applying a plurality of
compositions, preferably two, containing a dermatological or other
therapeutical agent to the skin from a single dispensing and applicator
system. The system has a plurality of compartmentalized applicator pads
which may be exposed and sequentially or simultaneously applied to the
skin area to be treated. The system is useful for administering separate
phases of an occlusive or semi-occlusive film-forming solution for
treating pathologies of the skin. When the phases are applied to and
dried upon the skin, a polymeric film forms to retain the therapeutical
agent in contact with the surface of the skin.

L39 ANSWER 19 OF 28 USPATFULL

ACCESSION NUMBER: 95:45054 USPATFULL
TITLE: Separately packaged applicator pads for topical
delivery of incompatible drugs
INVENTOR(S): Smith, James A., Chatham, MA, United States
Murphy, Betty J., Upper Montclair, NJ, United States
PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North
Caldwell, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5417674		19950523
APPLICATION INFO.:	US 1993-105877		19930811 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1992-986598, filed on 7 Dec 1992, now patented, Pat. No. US 5242433		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prebilic, Paul		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg & Woessner		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 7 Drawing Figure(s); 4 Drawing Page(s)

LINE COUNT: 1440

AB The present invention provides a system for applying a plurality, preferably two, dermatological agents to the skin from a single dispensing and applicator system comprising a plurality of compartmentalized applicator pads which may be exposed and sequentially applied to the afflicted skin area.

L39 ANSWER 20 OF 28 USPATFULL

ACCESSION NUMBER: 95:33906 USPATFULL

TITLE: Method and compositions for the production of chlorine dioxide

INVENTOR(S): Roozdar, Habib, Nesconset, NY, United States

PATENT ASSIGNEE(S): ARCO Research Co., Inc., Melville, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5407656		19950418
APPLICATION INFO.:	US 1994-231283		19940422 (8)
DISCLAIMER DATE:	20120110		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-93529, filed on 19 Jul 1993 which is a continuation-in-part of Ser. No. US 1992-846468, filed on 4 Mar 1992, now abandoned And a continuation-in-part of Ser. No. US 1992-980262, filed on 23 Nov 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Straub, Gary P.		
ASSISTANT EXAMINER:	Nguyen, N. M.		
LEGAL REPRESENTATIVE:	Coleman, Henry D., Sudol, R. Neil		
NUMBER OF CLAIMS:	25		
EXEMPLARY CLAIM:	10		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	1684		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention relates to a method for producing chlorine dioxide (ClO.sub.2) disinfecting solution which preferably minimizes the amount of residual chlorite ion (ClO.sub.2 -) so that the disinfecting solution can be used in a number of industries, preferably including the food, food processing, drinking water, pharmaceutical production, medical and dental industries. Chlorine dioxide generating solutions which are substantially corrosion free as well as gel formulations are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 21 OF 28 USPATFULL

ACCESSION NUMBER: 95:27337 USPATFULL

TITLE: Antipruritic agents and antipruritic compositions thereof

INVENTOR(S): Taguchi, Shigeru, Yokohama, Japan

Inokuchi, Miwako, Yokohama, Japan

Nakajima, Noriko, Yokohama, Japan

Inomata, Mie, Yokohama, Japan

Naito, Yasuo, Yokohama, Japan

PATENT ASSIGNEE(S): Shiseido Company Ltd., Tokyo, Japan (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 5401770	19950328
	WO 9210178	19920625
APPLICATION INFO.:	US 1992-917015	19920811 (7)
	WO 1991-JP1703	19911211
		19920811 PCT 371 date
		19920811 PCT 102(e) date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	JP 1990-415763	19901211
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Springer, David B.	
LEGAL REPRESENTATIVE:	Foley & Lardner	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	9	
LINE COUNT:	993	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An antipruritic agent comprising a zinc-amino acid complex, and an antipruritic composition containing said antipruritic agent at a concentration of 2.6.times.10.sup.-3 to 2.6.times.10.sup.-1 M.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 22 OF 28 USPATFULL

ACCESSION NUMBER: 94:104057 USPATFULL
 TITLE: Method of using a packaging system with folded applicator pads for topical drug delivery
 INVENTOR(S): Smith, James A., Chatham, MA, United States
 Murphy, Betty J., Upper Montclair, NJ, United States
 PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 5368581		19941129
APPLICATION INFO.:	US 1992-986349		19921207 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Green, Randall L.		
ASSISTANT EXAMINER:	Prebilic, Paul		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg & Woessner		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 1 Drawing Page(s)		
LINE COUNT:	1108		

AB The present invention provides a method for applying a plurality, preferably two, of dermatological agents to the skin from a single dispensing and applicator system comprising a plurality of compartmentalized applicator pads which may be exposed and sequentially or simultaneously applied to the afflicted skin area.

L39 ANSWER 23 OF 28 USPATFULL

ACCESSION NUMBER: 93:86897 USPATFULL
 TITLE: Separately packaged applicator pads for topical delivery of incompatable drugs
 INVENTOR(S): Smith, James A., Chatham, MA, United States
 Murphy, Betty J., Upper Montclair, NJ, United States
 PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5254109		19931019
APPLICATION INFO.:	US 1992-986598		19921207 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Green, Randall L.		
ASSISTANT EXAMINER:	Prebilic, Paul		
LEGAL REPRESENTATIVE:	Merchant, Gould, Smith, Edell, Welter & Schmidt		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 4 Drawing Page(s)		
LINE COUNT:	1433		

AB The present invention provides a method for applying a plurality, preferably two, dermatological agents to the skin from a single dispensing and applicator system comprising a plurality of compartmentalized applicator pads which may be exposed and sequentially applied to the afflicted skin area.

L39 ANSWER 24 OF 28 USPATFULL

ACCESSION NUMBER: 93:73819 USPATFULL
 TITLE: Packaging system with in-tandem applicator pads for topical drug delivery
 INVENTOR(S): Smith, James A., Chatham, MA, United States
 Murphy, Betty J., Upper Montclair, NJ, United States
 PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5242433		19930907
APPLICATION INFO.:	US 1992-986597		19921207 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Green, Randall L.		
ASSISTANT EXAMINER:	Prebilic, Paul		
LEGAL REPRESENTATIVE:	Merchant, Gould, Smith, Edell, Welter & Schmidt		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1269		

AB The present invention provides a method for applying a plurality, preferably two, dermatological agents to the skin from a single dispensing and applicator system comprising a plurality of compartmentalized applicator pads which may be exposed and sequentially or simultaneously applied to the skin area to be treated.

< L39 ANSWER 25 OF 28 USPATFULL

ACCESSION NUMBER: 93:31160 USPATFULL
 TITLE: Waterproof high-SPF sunscreen compositions
 INVENTOR(S): Han, Sie-Ta R., Williamsville, NY, United States
 PATENT ASSIGNEE(S): Bristol Myers Squibb, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5204090		19930420
APPLICATION INFO.:	US 1991-707473		19910530 (7)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

PRIMARY EXAMINER: Ore, Dale R.
LEGAL REPRESENTATIVE: Simon, M. S.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
LINE COUNT: 410

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sunscreen compositions which are waterproof and have high-SPF values comprise a water insoluble film-forming polymer, a polyoxypropylene ether of straight or branched chain alcohol (the emollient/solvent) and a sunscreen component containing at least one UVB type sunscreen and/or at least one UVA type sunscreen in a topical vehicle, preferably in the form of an alcoholic gel. In particular, the combination of a polyoxyalkylene ether of a straight or branched chain alcohol, a carboxylated acrylic copolymer and a sunscreen agent yields waterproof, high-SPF compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 26 OF 28 USPATFULL

ACCESSION NUMBER: 91:36230 USPATFULL
TITLE: Aqueous gels containing topical medicaments
INVENTOR(S): Blackman, Steven, New York, NY, United States
Ralske, Irene, North Bellmore, NY, United States
PATENT ASSIGNEE(S): Thames Pharmacal Co., Inc., Ronkonkoma, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5013545		19910507
APPLICATION INFO.:	US 1987-130445		19871209 (7)
DISCLAIMER DATE:	20070529		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Cashion, Jr., Merrell C.		
ASSISTANT EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Kirschstein, Ottinger, Israel & Schiffmiller		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	519		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Aqueous gel compositions incorporate topically active pharmaceutical agents in a non-irritating gel comprising from about 60 to about 90% ethyl alcohol and from about 0.5 to about 30% water together with at least one gelling agent. Optional additives include gel enhancers, gel neutralizers, ultraviolet absorbers, gel clarifying agents, anti-irritants and moisturizers. The gel compositions exhibit good bactericidal and bacteriostatic activity in addition to the pharmaceutical activity of the active topical ingredient. Methods of treating skin areas in mammals requiring topical medication comprise the application of the gel, with or without the incorporation of a topically active ingredient, to the affected skin areas 1 to 5 times daily.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 27 OF 28 USPATFULL

ACCESSION NUMBER: 80:16287 USPATFULL
TITLE: Injectable solutions and processes of using such
INVENTOR(S): Thiele, Geraldine H., New Oxford, PA, United States
PATENT ASSIGNEE(S): Oxford Hill, Ltd., New Oxford, PA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 4196218	19800401
APPLICATION INFO.:	US 1978-890239	19780327 (5)
DISCLAIMER DATE:	19900626	
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1976-724943, filed on 20 Mar 1976, now abandoned which is a continuation of Ser. No. US 1974-483010, filed on 25 Jun 1974, now patented, Pat. No. US 3982017 which is a continuation-in-part of Ser. No. US 1973-369236, filed on 12 Jun 1973, now patented, Pat. No. US 3924000 which is a continuation-in-part of Ser. No. US 1971-123830, filed on 12 Mar 1971, now patented, Pat. No. US 3767812, issued on 23 Oct 1973 Ser. No. Ser. No. US 1972-283662, filed on 25 Aug 1972, now patented, Pat. No. US 3805776 Ser. No. Ser. No. US 1972-283663, filed on 25 Aug 1972 And Ser. No. US 1971-113362, filed on 8 Feb 1971 , said Ser. No. US 1972-283662, filed on 25 Aug 1972 And Ser. No. US 1972-283663, filed on 25 Aug 1972 , each which is a continuation-in-part of Ser. No. US 1971-123830, filed on 12 Mar 1971 And Ser. No. US 1971-113362, filed on 8 Feb 1971 , said Ser. No. US 1971-123830, filed on 12 Mar 1971	
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Rosen, Sam	
LEGAL REPRESENTATIVE:	Fisher, Christen & Sabol	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	1974	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A liquefied composition which contains an effective amount of a non-necrotic sclerosing fatty acid salt, an effective amount of ethyl alcohol, a buffering agent, and a water carrier. The fatty acid salt is prepared from an unsaturated fatty acid having one double bond and from an alkali metal or an alkaline earth metal or an alkali metal compound or an alkaline earth metal compound. The liquefied composition has a pH between 9 and 11. The liquefied composition can be used for, among other things, faster healing of fractures, breaks and nonunions of bones without muscle atrophy, etc., by injecting the liquefied composition into the site of the fracture or nonunions. No cast is used.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L39 ANSWER 28 OF 28 USPATFULL
 ACCESSION NUMBER: 76:52007 USPATFULL
 TITLE: Injectable solutions and processes of using such
 INVENTOR(S): Thiele, Geraldine H., R.D. 1, Box 191B, New Oxford, PA, United States 17350

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3982017		19760921
APPLICATION INFO.:	US 1974-483010		19740625 (5)
DISCLAIMER DATE:	19900626		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1973-369236, filed on 12 Jun 1973, now patented, Pat. No. US 3924000 which is a continuation-in-part of Ser. No. US 1971-113362, filed on 8 Feb 1971, now patented, Pat. No. US 3741204 And Ser. No. US 1971-123830, filed on 12 Mar 1971, now patented, Pat. No. US 3767812 which is a continuation-in-part of Ser. No. 113362 , said Ser.		

No. 369236 which is a continuation-in-part of Ser.
No. US 1972-283662, filed on 25 Aug 1972, now patented,
Pat. No. US 3805776 which is a continuation-in-part of
Ser. No. 113362, said Ser. No. 123830 which is a
continuation-in-part of Ser. No. 283662 And Ser. No.
283663, now Defensive Publication No.

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Rosen, Sam
LEGAL REPRESENTATIVE: Christen & Sabol
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 2018

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Fractures, breaks and nonunions of bones are more readily healed without muscle atrophy, etc., by injecting a liquefied composition containing a non-necrotic vascular sclerosing fatty acid compound into the site of the fracture or nonunions. No cast is used. The preferred non-necrotic vascular sclerosing fatty acid compound is sodium oleate or ethanolamine oleate.

Bones can be fused together by injecting a liquefied composition containing a non-necrotic vascular sclerosing fatty acid compound into the interface region between the bones. Normally a cast or brace is not used. The preferred non-necrotic fatty acid compound is sodium oleate. Splints and diffused splints can be prepared using the bone fusing technique.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:42:47 ON 09 JAN 2002)

FILE 'REGISTRY' ENTERED AT 09:43:20 ON 09 JAN 2002

E CHOLECALCIFEROL/CN

L1 1 S E3

FILE 'MEDLINE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 09:44:48 ON 09 JAN 2002

L2 7452 S SUN(W) BURN OR SUNBURN OR RADIATION(W) DERMATIT?
L3 372928 S SUN(W) BURN OR SUNBURN OR RADIATION(W) DERMATIT? OR ULTRAVIOLET
L4 19 S L2 AND L1
L5 18 DUP REM L4 (1 DUPLICATE REMOVED)
L6 5 S (SUN(W) BURN OR SUNBURN) AND RADIATION(W) DERMATIT?
L7 4 DUP REM L6 (1 DUPLICATE REMOVED)
L8 720 S SUNBURN AND DERMATITIS
L9 228 S L8 AND ULTRAVIOLET
L10 219 DUP REM L9 (9 DUPLICATES REMOVED)
L11 46 S L10 AND ANTIOXIDANT
L12 3 S L4 AND "VITAMIN A" AND "VITAMIN E"
L13 2 DUP REM L12 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 10:08:53 ON 09 JAN 2002

E .ALPHA.-LIPOLIC/CN
E .ALPHA.-LIPOLIC ACID/CN
E .ALPHA.-LIPOLIC-/CN
E .ALPHA.-LIPOIC ACID/CN

L14 1 S E3

FILE 'MEDLINE, BIOSIS, USPATFULL, CAPLUS' ENTERED AT 10:11:23 ON 09 JAN
2002

L15 0 S L14 AND L13
L16 0 S L14 AND L5
L17 18 S L2 AND L5
L18 4 S L2 AND L14
L19 4 DUP REM L18 (0 DUPLICATES REMOVED)
L20 0 S L4 AND QUERCETIN
L21 30 S L2 AND QUERCETIN
L22 30 DUP REM L21 (0 DUPLICATES REMOVED)
L23 0 S L22 AND L1
L24 7 S L22 AND ("VITAMIN A" OR "VITAMIN E")
L25 3 S L24 AND ASCORBYL(W)PALMITATE
L26 3 DUP REM L25 (0 DUPLICATES REMOVED)
L27 0 S L1 AND "VITAMIN A" AND "VITAMIN E" AND ASCORBYL(W)PALMITATE A
L28 0 S L1 AND ("VITAMIN A" OR "VITAMIN E") AND ASCORBYL(W)PALMITATE
L29 0 S L1 AND ASCORBYL(W)PALMITATE AND QUERCETIN AND L14
L30 0 S ("VITAMIN A" OR "VITAMIN E") AND ASCORBYL(W)PALMITATE AND QU
L31 0 S (L1 OR ("VITAMIN A" OR "VITAMIN E")) AND ASCORBYL(W)PALMITAT
L32 1 S L4 AND (HYDROPHILIC(W)OINTMENT OR HYDROPHILIC(W)PETROLATUM O
L33 0 S L4 AND ?PANTHENOL
L34 126 S L2 AND ?PANTHENOL
L35 126 DUP REM L34 (0 DUPLICATES REMOVED)
L36 1 S L35 AND (HYDROPHILIC(W)OINTMENT OR ABSORPTION(W)BASE OR HYDR
L37 0 S L4 AND HYDROXYMETHYL(W)CELLULOSE
L38 28 S L2 AND HYDROXYMETHYL(W)CELLULOSE
L39 28 DUP REM L38 (0 DUPLICATES REMOVED)

L19 ANSWER 1 OF 4 USPATFULL

ACCESSION NUMBER: 2001:102409 USPATFULL
TITLE: Nutraceutical composition for protection against solar radiation
INVENTOR(S): Bragaglia, Anthony Joseph, Boston, MA, United States
PATENT ASSIGNEE(S): Protective Factors, Inc., Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6254898	B1	20010703
APPLICATION INFO.:	US 2000-578596		20000525 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Tate, Christopher R.		
ASSISTANT EXAMINER:	Flood, Michele		
LEGAL REPRESENTATIVE:	Mueller and Smith, LPA		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 2 Drawing Page(s)		
LINE COUNT:	501		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A nutraceutical composition, for the inhibition of photochemical damage to the skin and eyes induced by sunlight, particularly by exposure to ultraviolet radiation is disclosed. The blend is multifunctional and comprises a blend of chemopreventive natural products, which exert anti-radical mechanisms of prevention and intervention, anti-inflammatory effects, enhance the endogenous defense mechanisms, and also have the potential to reduce the radiation induced pigmentation. The active ingredients in the blend include green tea extract, lutein (zeaxanthin), lipoic acid, and selenomethionine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2002 ACS


ACCESSION NUMBER: 2001:693317 CAPLUS
DOCUMENT NUMBER: 135:257089
TITLE: Preparation and use of novel lipoic acid heterocyclic or benzene derivatives as medicines
INVENTOR(S): Harnett, Jeremiah; Auguet, Michel
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001068643	A2	20010920	WO 2001-FR764	20010315
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			FR 2000-3355	A 20000316


OTHER SOURCE(S):

CASREACT 135:257089; MARPAT 135:257089


GI



I



II



III

AB The invention concerns novel heterocyclic or benzene derivs., e.g., I [A = N:C(A')NH₂; A' = linear or branched C1-6-alkyl, 5-6 membered aryl or heterocycle; B1, B2 = (CH₂)_n; P = (CH₂)_g, R6-substituted phenylene; XY = O(CH₂)_r, NR₃(CH₂)_r, CO(CH₂)_r, CONR₃(CH₂)₂, NR₄CO(CH₂)_r, NR₃CONR₄(CH₂)_r; X'Y' = (CH₂)_r, (CH₂)_rO(CH₂)_r, (CH₂)_rNR₃(CH₂)_r, (CH₂)_rCO(CH₂)_r, (CH₂)_rCONR₃(CH₂)_r, (CH₂)_rNR₄CO(CH₂)_r, (CH₂)_rNR₃CONR₄(CH₂)_r; Z1, Z2 = 5-6 membered arom. heterocyclic, 4-7 non-arom. heterocyclic; Ph, C₆H₅R₅; R1, R2 = H, linear or branched C1-6-alkyl; R3, R4 = H, alkyl, alkoxy, aralkoxy, aralkoxy, aralkoxy; R5 = H, linear or branched C1-6-alkyl, (CH₂)_m-Q; Q = H, OH, CN, NH₂, alkoxy, (di)alkylamino; R6 = linear or branched C1-6-alkyl, (CH₂)_n-Q'; Q' = halogen, CF₃, OH, NH₂, CN, alkoxy, aralkoxy, alkoxy, alkylthio, (di)alkylamino; n = 0 - 6; g = 0 - 6; r = 0 - 6; m = 0 - 6] and II, or their pharmaceutically acceptable salts, comprising a lateral chain derived from lipoic acid, having an activity inhibiting NO-synthase enzymes producing NO nitrogen monoxide and/or are agents enabling regeneration of antioxidants or entities trapping reactive oxygen species (ROS) and intervening more generally in the redox status of thiol groups, methods for prepg. them, pharmaceutical compns. contg. them and their therapeutic use, particularly their use as NO-synthase inhibitors and/or as agents involved more generally in the redox status of thiol groups. Thus, thiophenecarboximidamide III.cntdot.HCl was prepd. from DL-thioctic acid, HS(CH₂)₂CH(SH)(CH₂)₄CO₂H, via amidation with N-(p-nitrophenyl)piperazine, nitro group redn. and condensation with S-methyl-2-thiophenethiocarboximide hydroiodide. III.cntdot.HCl was tested for inhibition of NO synthase from rat cerebellum (CI₅₀ = 4.5 .mu.M) and for its effect on oxidative stress induced by glutamate on HT-22 cell cultures (CE₅₀ = 4 .mu.M).

L19 ANSWER 3 OF 4 USPATFULL

ACCESSION NUMBER: 95:107924 USPATFULL

TITLE: Composition for enhancing lipid production in skin
INVENTOR(S): Rawlings, Anthony V., Wyckoff, NJ, United States
Zhang, Kelly H., Piscataway, NJ, United States
Kosturko, Richard, Nutley, NJ, United States
PATENT ASSIGNEE(S): Elizabeth Arden Co., Division of Conopco, Inc., New
York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5472698		19951205
APPLICATION INFO.:	US 1994-359758		19941220 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Kishore, Gollamudi S.		
LEGAL REPRESENTATIVE:	Mitelman, Rimma		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	908		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Skin treatment compositions for the enhancement of lipid production in the skin. Compositions contain a thiol, or an S-ester, in combination with L-serine or N-acetyl-L-serine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:998248 CAPLUS
DOCUMENT NUMBER: 124:97734
TITLE: Ester of retinol (vitamin A) with .alpha.-lipoic acid
for use in pharmaceuticals and cosmetics
INVENTOR(S): Weischer, Carl Heinrich
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4417038	A1	19951116	DE 1994-4417038	19940514

OTHER SOURCE(S): MARPAT 124:97734
AB Esters of retinol with .alpha.-lipoic acid or its analogs are useful in pharmaceuticals and cosmetics for treatment of inflammation, esp. of the skin (e.g. **sunburn**, eczema, seborrhea, and pyoderma), as well as of neurodermitis, psoriasis, necrosis, night blindness, bronchial carcinoma, allergy, aging, and sequelae of diabetes mellitus. Thus, 1.42-g capsules were prepd. contg. a mixt. of retinyl .alpha.-lipoate 20, Miglyol 795, sorbitol syrup 100, and glycerol 25 g.

=> d his

(FILE 'HOME' ENTERED AT 09:42:47 ON 09 JAN 2002)

FILE 'REGISTRY' ENTERED AT 09:43:20 ON 09 JAN 2002

E CHOLECALCIFEROL/CN

L1 1 S E3

FILE 'MEDLINE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 09:44:48 ON 09 JAN 2002

L2 7452 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT?
 L3 372928 S SUN(W)BURN OR SUNBURN OR RADIATION(W)DERMATIT? OR ULTRAVIOLET
 L4 19 S L2 AND L1
 L5 18 DUP REM L4 (1 DUPLICATE REMOVED)
 L6 5 S (SUN(W)BURN OR SUNBURN) AND RADIATION(W)DERMATIT?
 L7 4 DUP REM L6 (1 DUPLICATE REMOVED)
 L8 720 S SUNBURN AND DERMATITIS
 L9 228 S L8 AND ULTRAVIOLET
 L10 219 DUP REM L9 (9 DUPLICATES REMOVED)
 L11 46 S L10 AND ANTIOXIDANT
 L12 3 S L4 AND "VITAMIN A" AND "VITAMIN E"
 L13 2 DUP REM L12 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 10:08:53 ON 09 JAN 2002

E .ALPHA.-LIPOLIC/CN
 E .ALPHA.-LIPOLIC ACID/CN
 E .ALPHA.-LIPOLIC-/CN
 E .ALPHA.-LIPOIC ACID/CN
 L14 1 S E3

FILE 'MEDLINE, BIOSIS, USPATFULL, CAPLUS' ENTERED AT 10:11:23 ON 09 JAN 2002

L15 0 S L14 AND L13
 L16 0 S L14 AND L5
 L17 18 S L2 AND L5
 L18 4 S L2 AND L14
 L19 4 DUP REM L18 (0 DUPLICATES REMOVED)

L36 ANSWER 1 OF 1 USPATFULL

ACCESSION NUMBER: 92:7160 USPATFULL
TITLE: Cosmetic compositions containing N-alkoxyalkylamides
INVENTOR(S): Ciaudelli, Joseph P., Ramsey, NJ, United States
PATENT ASSIGNEE(S): Revlon, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5084270		19920128
	WO 8910121		19891102
APPLICATION INFO.:	US 1989-438503		19891215 (7)
	WO 1989-US1730		19890421
			19891215 PCT 371 date
			19891215 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-184858, filed on 22 Apr 1988, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Schenkman, Leonard		
LEGAL REPRESENTATIVE:	Blackburn, Julie		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	748		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Cosmetic compositions containing N-alkoxyalkylamides for use in providing moisturizing and/or softening properties to treat dry human skin and for use in other cosmetic applications and including also various novel N-alkoxyalkylamides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 09:42:47 ON 09 JAN 2002)

FILE 'REGISTRY' ENTERED AT 09:43:20 ON 09 JAN 2002
E CHOLECALCIFEROL/CN

L1 1 S E3

FILE 'MEDLINE, BIOSIS, CAPLUS, USPATFULL' ENTERED AT 09:44:48 ON 09 JAN 2002

L2 7452 S SUN(W) BURN OR SUNBURN OR RADIATION(W) DERMATIT?
L3 372928 S SUN(W) BURN OR SUNBURN OR RADIATION(W) DERMATIT? OR ULTRAVIOLET
L4 19 S L2 AND L1
L5 18 DUP REM L4 (1 DUPLICATE REMOVED)
L6 5 S (SUN(W) BURN OR SUNBURN) AND RADIATION(W) DERMATIT?
L7 4 DUP REM L6 (1 DUPLICATE REMOVED)
L8 720 S SUNBURN AND DERMATITIS
L9 228 S L8 AND ULTRAVIOLET
L10 219 DUP REM L9 (9 DUPLICATES REMOVED)
L11 46 S L10 AND ANTIOXIDANT
L12 3 S L4 AND "VITAMIN A" AND "VITAMIN E"
L13 2 DUP REM L12 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 10:08:53 ON 09 JAN 2002

E .ALPHA.-LIPOLIC/CN
E .ALPHA.-LIPOLIC ACID/CN
E .ALPHA.-LIPOLIC-/CN
E .ALPHA.-LIPOIC ACID/CN

L14

1 S E3

FILE 'MEDLINE, BIOSIS, USPATFULL, CAPLUS' ENTERED AT 10:11:23 ON 09 JAN
2002

L15 0 S L14 AND L13
L16 0 S L14 AND L5
L17 18 S L2 AND L5
L18 4 S L2 AND L14
L19 4 DUP REM L18 (0 DUPLICATES REMOVED)
L20 0 S L4 AND QUERCETIN
L21 30 S L2 AND QUERCETIN
L22 30 DUP REM L21 (0 DUPLICATES REMOVED)
L23 0 S L22 AND L1
L24 7 S L22 AND ("VITAMIN A" OR "VITAMIN E")
L25 3 S L24 AND ASCORBYL(W) PALMITATE
L26 3 DUP REM L25 (0 DUPLICATES REMOVED)
L27 0 S L1 AND "VITAMIN A" AND "VITAMIN E" AND ASCORBYL(W) PALMITATE A
L28 0 S L1 AND ("VITAMIN A" OR "VITAMIN E") AND ASCORBYL(W) PALMITATE
L29 0 S L1 AND ASCORBYL(W) PALMITATE AND QUERCETIN AND L14
L30 0 S ("VITAMIN A" OR "VITAMIN E") AND ASCORBYL(W) PALMITATE AND QU
L31 0 S (L1 OR ("VITAMIN A" OR "VITAMIN E")) AND ASCORBYL(W) PALMITAT
L32 1 S L4 AND (HYDROPHILIC(W) OINTMENT OR HYDROPHILIC(W) PETROLATUM O
L33 0 S L4 AND ?PANTHENOL
L34 126 S L2 AND ?PANTHENOL
L35 126 DUP REM L34 (0 DUPLICATES REMOVED)
L36 1 S L35 AND (HYDROPHILIC(W) OINTMENT OR ABSORPTION(W) BASE OR HYDR